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Abstract  
Alzheimer’s disease (AD) is a fatal disorder with no apparent cure. Early-onset AD 
(EOAD) occurs in individuals before the age of 65, and late-onset AD (LOAD) occurs in 
individuals age 65 and older. Past studies have proven that AD is fatal among Americans 
age 65 and older. The disease is characterized by impairments in memory and executive 
function as well as other cognitive and behavioral problems. The research questions 
addressed by this sequential, mixed-method study compared EOAD and LOAD by 
exploring common behavioral/cognitive symptoms and stage levels of AD. Research 
participants were recruited from the Alzheimer’s Association who were members of 
caregiver support groups and cared for an individual with AD. The qualitative component 
of this study consisted of a qualitative interview given to caregivers (N = 6), which was 
audio-recorded and transcribed verbatim using the 6-phase thematic analysis. 
Sequentially, the quantitative component of this study consisted of the BEHAVE-AD and 
Short IQCODE instruments, which were filled out and completed by caregivers (N = 20) 
on behalf of patients with probable AD. These data were analyzed using 1-way ANOVA, 
with the alpha set at 0.05. Integration of qualitative and quantitative results indicated no 
differences in cognitive or behavioral symptoms of either EOAD or LOAD care 
recipients. These findings have implications for positive social change by continually 
involving caregiver participants in future studies. Doing so can ensure that care 
recipients, whether they have been diagnosed at EOAD or LOAD, have a voice. 
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Chapter 1: Introduction to the Study  
Introduction 
Alzheimer’s disease (AD) is the sixth leading cause of death in the United States 
(Alzheimer’s Association, 2016). AD is also the fifth leading cause of death among 
Americans age 65 and older. Approximately 5.4 million Americans suffer from this 
neurodegenerative disease (AA, 2016). The financial and medical cost to treat AD is 
between $200 and $600 billion, annually. The average age of diagnosis is 65 (Duke 
University Medical Center, 2002). In the next decade there will be 10 million more 
individuals diagnosed with AD due to the baby boomer generation—those born between 
1946 and 1964—turning 65 and older.  By the year 2050, the annual cost to treat this 
population will increase to well over $1 trillion (Okie, 2011). Diagnosis of AD increases 
significantly with age. The Alzheimer’s Association Report (2012) indicated that there 
are about 53 new cases per 1000 individuals aged 65 to 74 years, 170 new cases per 1000 
individuals aged 75 to 84 years, and 231 cases per 1000 individuals 85 and older (the 
oldest old). 
 According to the Alzheimer’s Association (2012), aging baby boomers will 
increase the percentage of Americans living longer and being amongst the oldest old (85 
and older). Therefore, this increases their chances of developing AD. Age is a consistent 
risk factor for AD (Kalaria et al., 2008). The oldest baby boomer turned 65 years old in 
2011 and the youngest baby boomer will turn 65 years old in 2029. The Centers for 
Disease Control and Prevention and the U.S. Census Bureau estimate that by 2030, those 
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aged 65 and older will double in population and these 71 million “older” Americans will 
account for 20% of the entire population (AA, 2012). 
Background 
 Alzheimer’s disease (AD) is a neurodegenerative brain disorder of unknown 
cause with neuropathological and neurochemical features. The disorder is usually 
harmful in onset and increases slowly, but steadily, over a period of several years 
(Jongbloed et al., 2013). Once individuals have been diagnosed with AD, they can live 
with the disease, on average, 4 to 8 years before death (AA, 2013). However, there are 
those who may live as long as 20 years after being diagnosed with AD. 
 A significant number of researchers and scientists are in agreement that vital 
processes are interrupted by amyloid plaques and neurofibrillary tangles, which are 
considered to be the two hallmarks of AD (Braak & Tredici, 2012; Cummings, Golde, 
Sano, & Tariot, 2007; Jongbloed et al., 2013; Kar et al., 2004; Yu et al., 2013). The role 
these microscopic abnormal structures play in the terminal disease are not clear. 
However, once these abnormalities spread, causing shrinkage of the brain, certain 
memory components suffer. Jongbloed et al. (2013) explained that amyloid plaques 
contain a 42-amino acid-long isoform of amyloid β (Aβ42) and that neurofibrillary tangles 
consist mainly of hyper-phosphorylated forms of the microtubule-associated protein tau 
(TAU). Formations of these abnormal proteins are thought to contribute to the loss or 
degeneration of neurons in the brain and the ensuing symptoms of Alzheimer's disease. 
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 Duara et al. (2013) summarized the importance of amyloid in AD. They 
hypothesized that amyloid deposition in the brain may be the earliest detectable 
biomarker among subjects destined to develop AD. Brain amyloid levels increase from 
6% in 50- to 59-year-old individuals to 50% in those 80-years and older. Elevated brain 
amyloid load has been associated with memory decline, increased risk for progression to 
mild cognitive impairment (MCI), and dementia among elderly individuals who are non-
demented, but not among AD patients in whom amyloid levels have stabilized. Brain 
amyloid load is also associated with hippocampal (HP) volume loss and cognitive 
impairment among elderly, healthy subjects and patients with MCI. These atrophic 
changes, which may be present for many years before clinical symptoms appear or 
cognitive decline occurs, represent the neurodegenerative element of AD, and the 
possible cause of cognitive impairment and eventual progression to the disease (Duara et 
al., 2013). Amyloid plaques are considered an initial event in AD, which is followed by 
neurofibrillary tangle formation, neuronal loss and dysfunction, and ultimately dementia. 
 Hyman et al. (2012) further explained the neuropathology of AD. As mentioned 
above, neurofibrillary tangles (NFTs) are intraneuronal fibrils primarily composed of 
abnormal tau. NFTs are commonly observed in the limbic regions early on in AD, but 
depending on the stage of the disease, NFTs can also be present in other regions of the 
brain. Both amyloid plaques and NFTs are widely distributed throughout the neocortex. 
However, it must be noted that these two biomarkers of AD do not reflect the complete 
molecular pathology of the disease.  
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 As further research is conducted on AD, more questions continue to be raised. 
The Consensus Committee (Hyman et al., 2012), which involved a panel from the United 
States and Europe, recommended an “ABC” staging protocol for AD neuropathologic 
changes, based on three morphological characteristics of AD: amyloid plaques (A), NFTs 
(B), and neuritic plaques (C). The neuritic plaques were most closely associated with 
neuronal injury. They were characterized by occurrence of dystrophic neuritis, greater 
local synapse loss, and glial activation (Hyman et al., 2012). 
 Research studies conducted on Alzheimer’s disease have investigated memory 
loss/impairment and how it affects patients’ behavior. Castel, Balota, and McCabe (2009) 
examined whether aging and AD influenced patient selection of what is important to 
recall, attending to information, and later retrieving the information. The pattern 
suggested that relative to healthy aging, AD leads to impairments in strategic control at 
encoding and value-directed recall, crucial elements of executive control of cognitive 
processes. The National Institute of Aging (2009) provided background information for 
causes, signs, and symptoms of AD relating to memory loss and thinking skills.  
 This study examined cognitive/behavioral symptoms of AD patients comparing 
those with EOAD to those with LOAD. A more accurate understanding of the 
progression of the disease may contribute to efforts at prevention and treatment.  
Problem Statement 
  This study explored collaboration on the part of many scientists, researchers, and 
neuropsychologists. There is no known cure for AD (AA, 2013). There are numerous 
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research studies that have been conducted on AD patients regarding cognitive functioning 
related to a variety of phenomena  such as memory impairment (Berwig, Leicht, Hartwig, 
& Gertz, 2011; Gagnon & Belleville, 2011; Mathias & Burke, 2009), personality traits 
(Duberfstein et al., 2011), emotion perception (Phillips et al., 2010), motivation 
(Forstmeier, et al., 2011), and attentional control (Coubard et al., 2011). The fact still 
remains that those most significantly affected by AD are individuals ranging from age 65 
years to 85 years. This risk factor will most likely affect a significant number of future 
baby boomers (AA, 2013). As a result, in January 2011, President Barack Obama passed 
the National Alzheimer’s Project Act (NAPA). With the help of the U.S. Department of 
Health and Human Services (HHS), this law was created to reduce the prevalence of or 
find a cure for Alzheimer’s disease by: (a) coordinating research and services across all 
federal agencies regarding AD; (b) speeding up treatment developments that would slow 
down, prevent, or overturn the course of the disease; (c) improving coordination of care, 
treatment, and early diagnosis of AD; (d) improving outcomes for demographic 
populations who are at risk for AD; and (e) forming collaborative efforts globally with 
international bodies to fight AD (NAPA, 2011). Therefore, comparing symptoms and 
stages of groups with diagnosis of EOAD to that of LOAD may contribute to a greater 
increase in our understanding of the progression of the disease. Such an increase in 
understanding may contribute to more effective efforts at prevention, diagnosis, and 
treatment. 
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Aging changes 
 The National Institutes of Health (NIH, 2013) explained that as individuals age 
the brain and nervous system go through natural changes. The brain and spinal cord lose 
nerve cells and weight (atrophy). Nerve cells may begin to pass messages more slowly 
than in the past. Waste products can collect in the brain tissue as nerve cells break down, 
causing abnormal brain changes such as formation of amyloid plaques and neurofibrillary 
tangles.  Breakdown of nerves can affect human senses. Reduced or lost reflexes or 
sensation can lead to problems with movement and safety. 
 Cells are the basic building blocks of tissues (Feng & Gao, 2011) and all cells 
experience changes with aging (NIH, 2013). They become larger and are less able to 
divide and multiply. Many cells begin to function abnormally and progressive loss of 
neural cells can occur, especially in the case of AD patients (Feng & Gao, 2011). Waste 
products build up in tissues with aging. Therefore, many AD patients loose oxygen and 
nutrients in brain cells; as well as the ability to remove carbon dioxide and wastes 
(Cheung & Ip, 2011). Mass loss occurs in these tissues, causing them to become lumpy or 
more rigid, which results in a process called atrophy (NIH, 2013). Feng and Gao (2011) 
suggested cell replacement as an alternative option for fighting neurodegenerative 
disorders such as AD. 
 Because of cell and tissue changes, organs (e.g., the brain) also change as 
individuals age. Aging organs slowly lose function. Most people do not notice this loss, 
because human organs are not used to their fullest ability (NIH, 2013). Conducting 
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research studies that explored cognitive/behavior symptoms of groups diagnosed with 
AD and comparing AD patients diagnosed before age 65 to those diagnosed age 65 and 
over, can help better understand the progression of this disease.  
 This study allowed me to explore the connection of cognitive/behavioral 
symptoms of AD to time of onset, which was beneficial. AD patients are considered to be 
early onset (EOAD) before the age of 65 and late onset (LOAD) at 65 years and older. 
LOAD is the most common type of AD. These factors allowed me to form two research 
groups.  I compared both cognitive and behavioral symptoms  of individuals with EOAD 
and LOAD.  Then once I conducted statistical analysis, cognitive and behavioral 
symptoms scores were determined for each group. As a result of my research, future 
treatment, possible prevention, and early intervention/screening can be managed and 
shared across all professional disciplines (academic, scientific, private, public, 
government, etc.). This, in turn, could lead to more collaboration, which could increase 
the probability of finding a cure or at least more effective treatment for AD. 
Purpose of the Study 
 This study explored Alzheimer’s disease (AD), which is the most common form 
of dementia (Alzheimer’s Association, 2009), has no known cure, and is fatal to those 
who have it. In particular, this study examined whether there is a difference in 
progression of the disease based upon early-onset AD (EOAD) or late-onset AD 
(LOAD). The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition 
([DSM-V] APA, 2013), lists Alzheimer’s disease under the category neurocognitive 
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disorders (NCDs). The criteria for various NCDs are based on specified cognitive 
domains such as complex attention, executive function, learning and memory, language, 
perceptual-motor function, and social cognition. Criteria are met for either probable or 
possible Alzheimer’s disease with or without behavioral disturbance and severity. By 
definition, major or mild NCDs affect functioning, given the central role of cognition in 
human life. Thus the criteria for the disorders and the threshold for differentiating mild 
from major NCD are based in part on functional assessment. These domains and 
descriptors in the DSM-V are slightly different from those included in the DSM-IV.  For 
the diagnostic criteria for Major or Mild Neurocognitive Disorder due to Alzheimer’s 
disease see Appendix A.   
 Vanderstichele et al. (2012) indicated that accurate clinical diagnostic criteria for 
AD are poor because the disease is a complex disorder with overlapping profiles. The 
authors posit that depending on the research, clinical diagnoses of AD are correct only 
63% to 90% of the time. Clinical diagnosis made at first visit in confirmed cases of AD 
results in only 68% of AD cases being straightforward and correct. In remaining cases, 
16% of clinical diagnoses made at first visit are incorrect or doubtful. In the early stages 
of the disease, diagnostic accuracy is much lower. Vanderstichele et al. (2012) stated that 
the development of revised diagnostic criteria that included biomarkers could improve 
diagnostic accuracy of AD significantly.  
 Shoji et al. (2000) and Sunderland et al. (2003) confirmed the relevance of the 
neurofibrillary tangles and amyloid plaques associated with AD by using these 
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biomarkers for AD present in cerebrospinal fluid (CSF). This research and other studies 
revealed that combined use of these markers  (Blennow & Hampel, 2003; Engelborghs et 
al., 2008; Fagan et al., 2003; Sjogren, Andreasen, & Blennow, 2003) resulted in higher 
sensitivity and specificity and met the requirements for discriminating AD from other 
specific neurological disorders and normal aging (Vanderstichele et al., 2012).  
Vanderstichele et al. (2012) posited that biomarker assessments were helpful in 
addressing the AD etiological diagnosis in nonamnestic presentations of AD. In most 
cases of posterior cortical atrophy, typical biological AD patterns have low amyloid 
deposits with low tau levels, confirming initial reports of underlying AD pathology in 
posterior cortical atrophy after autopsy. In addition, low amyloid deposit levels together 
with high levels of tau are reliable signatures of an underlying pathology of AD (Braak & 
Tredici, 2012; Kawas et al., 2013; Vanderstichele et al., 2012).  
 It has been more than 100 years since AD was first identified (AA, 2012), but 
only within the last 30 years has research by scientists, academics, government programs, 
and private and public sectors gained financial-momentum and exposure. Research into 
AD symptoms, risk factors, causes, and treatment has uncovered a considerable amount 
of information in regards to AD. However, precise physiological changes that trigger AD 
development still remain unidentified (AA, 2012). 
 Over the past 150 years, advances in the treatment of heart disease and cancer are 
responsible for postponement of mortality and a marked change in aging 
biodemographics. In addition, other improvements in public health and medical care 
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during the 20
th
 century have led to considerable increases in life expectancy (Carrillo et 
al., 2013). As a result, the principal causes of death have shifted dramatically from 
chiefly infectious diseases to cardiovascular disease, cancers, and increasingly, 
progressive neurodegenerative dementias such as AD (Kling, Trojanowski, Wolk, Lee, & 
Arnold, 2013). If this trend continues, individuals who were  born at the beginning of the 
21
st
 century can expect to live past the age of 100, nearly double the average life 
expectancy only one century ago (Carrillo et al., 2013). 
 Most individuals with AD usually live 4 to 8 years after their diagnosis (AA, 
2012).  However, there are those who live as long as 20 years after being diagnosed.  
EOAD patients are diagnosed before the age of 65 and LOAD patients are diagnosed on 
or after the age of 65. By studying and comparing symptoms of EOAD and LOAD 
patients, it may be possible to identify the characteristics that can help increase patient 
survivability in general. These individuals live longer in the severe stage of the disease 
than any other stage. This slow progression of AD usually means a frightening fate for 
AD patients, not to mention having to spend the rest of their years in a nursing home. 
Two-thirds of individuals, who die of dementia, usually do so in nursing homes as 
compared to 20% of those who die from cancer or 28% of those who die from all other 
conditions (AA, 2012). AD is the sixth leading cause of death. In addition, slow 
progression of the disease also has a statistical impact on public health (Okie, 2011).  
There is an incomplete understanding of the differences in disease progression 
between EOAD and LOAD (Panagyres & Chen, 2013; 2014). Disease progression of 
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EOAD and LOAD will be examined to determine whether or not cognitive/behavioral 
symptoms have a relation to AD time of onset. EOAD is a rare form of Alzheimer’s 
disease in which individuals are diagnosed with the disease before age 65 (AA, 2014). 
LOAD is the most common form of Alzheimer’s disease, in which individuals are 
diagnosed with the disease after age 65 (AA, 2014). There are suggestions that the 
underlying pathology may be different when it comes to cognitive and behavioral 
symptoms (Eriksson et al., 2014).  Eriksson et al. (2014) concluded that there are 
differences between EOAD and LOAD in demographics, diagnostic work-up and 
pharmacological treatment. The purpose of this study was to investigate 
cognitive/behavioral symptoms as related to time of onset, whether that of EOAD and/or 
LOAD patients.  
Research indicates that memory loss, impairment, and distortion are core features 
of Alzheimer’s disease (Sternberg, 2009). Brain structures involved in memory deficits 
are also linked to behavior functions (Nadel & Peterson, 2013: Yu et al., 2013).  In early-
onset AD, genetic risk factors include amyloid precursor protein (APP), presenilin 1 
(PSEN1), and presenilin 2 (PSEN2). In late-onset AD, the apolipoprotein E (ApoE) 
protein is also an important genetic risk factor, having at least three variations of its kind 
called E2, E3, and E4 alleles. According to previous studies, mutations in these various 
genes have been presented on AD timelines according to age (Bagyinszky, Youn, An, & 
Kim, 2014). The following research questions and hypotheses guided this study. 
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Research Questions and Hypotheses 
RQ1: Are there differences in cognitive symptoms between EOAD patients and LOAD 
patients? 
H01: EOAD patients have the same cognitive symptoms as LOAD patients. 
Ha1: EOAD patients have different cognitive symptoms than LOAD patients. 
RQ2: Are there differences in behavioral symptoms between EOAD patients and LOAD 
patients? 
H02: EOAD patients have the same behavioral symptoms as LOAD patients. 
Ha2: EOAD patients have different behavioral symptoms than LOAD patients. 
Framework 
 I used the traditional memory model for this research. This model indicated that 
memory is the means by which we retain and draw on prior experiences to utilize 
information for present experience. Atkinson and Shiffrin (1968) posited that memory 
can be perceived in three memory stores: sensory memory, short-term memory, and long-
term memory. When AD is present, memory is lost, specifically episodic memory in the 
early stage of AD; as the disease progresses, semantic memory is impaired. However, 
non-declarative memory is still intact until near death (Sternberg, 2009), which will be 
discussed in further detail in Chapter 2. 
Further research is needed to understand specific stages of the disease in 
comparative groups: EOAD patients versus LOAD patients, as well as behaviors noticed 
after cognitive decline. As a result, this study was pursued using quantitative informant 
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instruments, the Behavioral Pathology in Alzheimer’s disease (BEHAVE-AD) (Reisberg, 
Borenstein, Salob, Ferris, Franssen, & Georgotas, 1987) and the Short Form of the 
Informant Questionnaire on Cognitive Decline in the Elderly (Short IQCODE) (Jorm, 
1994) as well as a qualitative interview conducted with several of the participating 
caregivers on behalf of their AD patients/family members. The research design was a 
mixed method approach. 
Nature of the Study 
 I used a mixed methodology in this study, both quantitative and qualitative 
approaches. Data was obtained from caregivers of individuals who had been diagnosed 
with AD. The caregivers were given a demographic background questionnaire (Bivin, 
2013) to complete on behalf of the individual with AD. The BEHAVE-AD Informant 
instrument (Reisberg et al., 1987) and the Short IQCODE (Jorm, 1994) were completed 
by the caregiver on behalf of the AD patient as well. A qualitative interview was given to 
several participants to obtain personal perspectives and to explore symptoms in more 
detail. Because the cognitive and behavioral informant instruments, and the demographic 
questionnaire, were filled out by the caregiver instead of the actual AD patient, 
information was not as precise.  The BEHAVE-AD Informant assessed behavioral 
symptoms of the AD patient and the Short IQCODE assessed cognitive symptoms.  But 
before these quantitative tools were presented, I conducted a qualitative interview with 
six of the participant caregivers. Once the caregiver completed each assessment, this 
information was scored and categorized into EOAD/LOAD. To obtain the present stage 
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of the AD patient, a definition for each stage was presented on the demographic 
questionnaire, which I handed out to Alzheimer Association Support groups for 
caregivers in various locations throughout the state of Texas. Further details were 
discussed in Chapter 3. 
 Information was obtained from experts in the fields of psychology and psychiatry, 
as well as from dissertation committee chair and members, to assist in determining 
relevant symptoms and stage levels of the AD population. I collected data from the 
Alzheimer’s Association, the National Institute of Aging, as well as various partnerships. 
In regards to the Alzheimer’s Association, the caregivers were the sole source of 
information on behalf of the sample of the AD patient population. The same method was 
used to determine the AD stage level; stage levels were defined according to Reisberg’s 
seven-stage framework in Alzheimer Association’s website (AA, 2013).  Quantitative 
analysis drawn from the data (information from the caregiver and symptoms endorsed 
from research instruments) provided statistical inferences of the most salient symptoms. 
In addition, it was the intent of this study to explore and obtain themes/paradigms that 
originated from the qualitative aspect of the research. 
Definition of Terms 
 The following are definitions of cognitive and neurological terms used in 
describing Alzheimer’s disease. 
 Acetylcholine (ACh): a key neurotransmitter that modulates neural processing 
within the cortex and between the thalamus and cortex (Savage, 2012). 
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 Alzheimer’s disease: the major cause of dementia in old age, characterized by 
neurofibrillary tangles, amyloid plaques, and neuron loss (Pinel, 2009). 
 Amyloid: a protein that is normally present in small amounts in the human brain 
but is a major constituent of the numerous plaques in the brains of Alzheimer’s patients 
(Pinel, 2009). 
 Apolipoprotein E: a gene product that is a significant risk factor for late onset 
Alzheimer’s disease (Bagyinsky et al., 2014). 
 Atrophy: degeneration or wasting away of an organ, structure, or body part 
through disease, inadequate nutrition, or disuse (Colman, 2006). 
 Cerebrospinal fluid (CSF): colorless fluid produced in the brain that fills the 
subarachnoid space that circulates through the cerebral ventricles before flowing 
passively into the venous bloodstream (Colman, 2006; Pinel 2009). 
 Declarative memory: A storage system for declarative knowledge, involving 
structures in the “temporal lobes, especially the hippocampus. Information contained in it 
is acquired by a form of learning that requires conscious awareness and that occurs 
quickly (Coleman, 2006). 
 Early-onset Alzheimer’s disease (EOAD): a rare form of Alzheimer’s disease in 
which individuals are diagnosed with the disease before age 65 (AA, 2014). 
 Episodic memory: A type of long-term memory for personal experiences and 
events (Coleman, 2006). 
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 Explicit memory: Memory that is revealed when performance on a task requires 
conscious recollection of information previously learnt (Coleman, 2006). 
 Familial AD: early-onset Alzheimer’s disease that runs in families, where copies 
of one or two genes are inherited from an individual’s parents (Bagyinsky et al., 2014). 
 Genetic mutation: a permanent change in the DNA sequence that makes up a 
gene. Gene mutations occur in two ways: they can be inherited from a parent or acquired 
during a person’s lifetime (NIH, 2014). 
 Implicit memory: A type of memory that is revealed when learning facilitates 
performance on a task that does not require conscious  or intentional recollection of what 
was learnt (Coleman, 2006). 
 Late-onset Alzheimer’s disease (LOAD): the most common form of Alzheimer’s 
disease in which individuals are diagnosed with the disease after age 65 (AA, 2014). 
 Mild Cognitive Impairment: a condition characterized by slight amnesia without 
dementia or other forms of cognitive impairment, often a precursor of Alzheimer’s 
disease (Colman, 2006). 
 Mutation: a process that creates genetic variation or a change in the “genes or 
chromosomes of a cell” (Colman, 2006).  
 Neurofibrillary tangles: a knotty mass of neurofibrils and insoluble fibers 
composed chiefly of breakdown products of the tau protein, occurring in the brains of 
most people over 70 years old and found abundantly in the hippocampi and amygdalae of 
patients with Alzheimer’s disease and other disorders (Colman, 2006). 
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 Neurogenesis: the generation of new neurons to replace damaged ones (Colman, 
2006). 
 Neurons: cells of the nervous system that are specialized for receiving and 
transmitting electrochemical signals (Pinel, 2009). 
 Neurotransmitter: a small amine or peptide but also a substance such as the gas 
nitric oxide, by which a neuron communicates with another neuron or with a muscle or 
gland via a synapse (Colman, 2006). 
 Non-declarative memory: Memory for non-declarative knowledge, involving 
memory systems that do not draw on the individual’s general knowledge (Coleman, 
2006). 
 Precursor: a forerunner, or something that precedes or heralds something else; in 
particular, a chemical substance from which another more important substance is derived 
or synthesized (Colman, 2006). 
 Procedural memory: a form of non-declarative memory, which is a storage 
system for procedural knowledge, information in it being acquired through a form of 
learning that is relatively slow, requiring repetition over many tasks, and often occurring 
without conscious awareness (Coleman, 2006). 
 Semantic memory: A type of long-term memory for factual information about the 
world, excluding personal episodes in one’s life (Coleman, 2006). 
 Sporadic AD: early-onset Alzheimer’s disease without any family history or 
inheritance pattern of mutated genes, like that of familial AD (Bagyinsky et al., 2014). 
18 
 
Significance 
 The significance of this study is that it contributed to the current knowledge base 
regarding AD and illuminated similar/different symptoms and stages related to early 
versus late onset of the disease. Many researchers have focused attention on the temporal 
lobe of the brain because amyloid plaques and neurofibrillary fibers play important roles 
in the spread of AD to brain tissues in this area (Good, Hale, & Staal, 2007). 
Khachaturian, Mielke, and Khachaturian (2012) brought attention to cognitive 
dysfunction during various stages of AD, and how it influenced patients’ behaviors. 
In Chapter 2, I will discuss research that has and is being conducted on memory 
and behavioral aspects of AD.  There maybe evidence-based knowledge revealed from 
studying symptoms and stages of the disease by focusing on the comparison of EOAD to 
that of LOAD. This could lead to better and more meaningful ways for caregivers and 
clinical professionals to detect/identify symptoms of AD patients at specific stages of the 
disease. 
Summary 
 This study was conducted to contribute to the current knowledge base concerning 
AD presented by previous researchers. AD is the sixth leading cause of death in the 
United States, but is the fifth leading cause of death for individuals aged 65 and older 
(AA, 2016). The financial burden to treat AD is approximately $200 to $600 billion 
annually. However, when the baby boomer generation reaches the critical age when the 
onset of AD appears, the financial cost could increase to $1 trillion, annually (Okie, 
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2011). Considering there is no known cure for AD, this study focused on and compared 
symptoms and stages of AD in groups who had EOAD versus those who had LOAD. My 
intent was to offer a better understanding of the progression of AD. These implications 
could in turn be shared with other researchers, scientists, and clinical professionals to 
improve future treatment/prevention outcomes. In addition, this research provided 
information that could contribute to the development of treatments to address the 
continued increase in the aging population’s possibility of inheriting or developing AD. 
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Chapter 2: Literature Review 
Introduction 
Alzheimer’s disease (AD) is the most common form of dementia (Alzheimer’s A, 2009). 
Dementia is impairment or loss of memory, especially evident in the learning of new 
information, and of thinking, language, judgment, and other cognitive faculties, without 
clouding of consciousness (Colman, 2006). AD is a type of dementia or condition that 
develops when neurons, or nerve cells, in the brain die. Death of these nerve cells causes 
deficits in an individual’s memory, behavior, and ability to think. These impairments 
caused by AD can prevent an individual from performing basic bodily functions and 
eventually cause death (Pinel, 2009). 
 The Alzheimer’s Association (AA, 2016) reports that in the United States, 
Alzheimer’s disease is the sixth leading cause of death. In Americans over the age of 65 
years (LOAD), it is the fifth leading cause of death. It is estimated that 5.4 million 
Americans have AD including 200,000 individuals who are considered early onset 
sufferers (EOAD), diagnosed before the age of 65 (AA, 2016). Over the next decade, 10 
million baby boomers are expected to develop AD.  By the year 2050, the prevalence of 
AD will increase to between 11 million and 16 million cases across all racial and ethnic 
groups (LOAD), specifically those over age 85 (AA, 2012). Other causes of death such as 
stroke, heart disease, and prostate cancer, have decreased by 20%, 13%, 8%, respectively, 
in the past several years. However, deaths from AD have increased by 66% (AA, 2012). 
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In 2012, a total of $200 billion dollars were expended on the care of individuals with AD 
and other dementias. 
 Although AD was identified more than 100 years ago, there is no known cure for 
this degenerative disease (AA, 2012). It was only in the past 30 years that widespread 
attention has been given to research that involved AD symptoms, risk factors, and 
treatment (Cummings, Golde, Sano, & Tariot, 2007; Khachaturian, Khachaturian, & 
Thies, 2012). It has only been a few years since collaborations among private, 
government, and academic institutions have been formed to create a national research 
initiative (NAPA, 2011). Following is an explanation of how this literature review was 
accomplished. 
Literature Search 
 The literature search was conducted by retrieving articles from Walden University 
library using the PSYCArticles database, peer-reviewed articles retrieved from 
subscription copies of Alzheimer’s & Dementia: The Journal of the Alzheimer’s 
Association (2012/2013), Archives of General Psychiatry, Clinical Geriatrics: A Clinical 
Journal of the American Geriatrics Society, Current Psychiatry, Cognitive Science, and 
the Psychological Review. I used the Alzheimer’s Organization website to review 
updated information that had been presented by members of Alz.org.  I also used several 
books to compare information and use during the search process. Words or phrases that I 
used to retrieve peer reviewed articles included: Alzheimer’s disease, mild cognitive 
impairment, symptoms of Alzheimer’s disease, risk factors for Alzheimer’s disease, 
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memory loss, caregivers and Alzheimer’s disease, stages and progression and 
Alzheimer’s disease. All sources were evaluated for relevancy of topics concerning 
Alzheimer’s disease. 
Amyloid Hypothesis and Memory Theory of Alzheimer’s Disease 
 AD is a syndrome consisting of deficits in memory, reasoning, and judgment, and 
changes in behavior, communication abilities, and mood (Berwig, Leicht, Hartwig, & 
Gertz, 2011; Gagnon & Belleville, 2011; Mathias & Burke, 2009). Duara et al. (2013) 
posited that Alzheimer’s disease occurs as a result of protein accumulation in key areas of 
the brain linked to the creation and maintenance of memories and the accuracy of those 
memories. Activity in the hippocampus increases in response to this protein accumulation 
in an effort to protect these memories. Over time this excess activity can cause damage to 
the hippocampus as AD progresses (Gauthier & Molinuevo, 2013).Although there has 
been a significant increase in understanding of how the brain changes with AD, 
researchers do not know the cause of this fatal disorder.  
 The amyloid hypothesis is the leading theory explaining AD pathogenesis. Braak 
and Del Tredici (2012) posited that aberrant processing of amyloid precursor protein 
(APP) leads to the accumulation of insoluble amyloid in the brain. Lelos, Thomas, Kidd, 
and Good (2011), Lim et al. (2013), and Nekkiksimmons et al. (2013) published literature 
reaching the same conclusion. Neurotoxic amyloid β (Aβ) peptide Aβ42 is an APP 
processing product. The gathering or aggregation of Aβ42 into multiple oligomeric forms 
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and deposition in amyloid plaques is considered an initial event in AD, which is followed 
by neurofibrillary tangle formation, neuronal loss and dysfunction, and then dementia.  
Genetic Varieties of Alzheimer’s disease 
 Neuropathological hallmarks of familial and sporadic AD include extracellular 
parenchymal and cerebrovascular amyloid deposits, intracellular neurofibrillary tangles, 
and loss of neurons and synaptic integrity in explicit areas of the brain (Kar, 
Slowikowski, Westaway, & Howard, 2004; Yu et al., 2013). Genetic and environmental 
factors can both contribute to AD development.  
Early onset AD (EOAD)/Familial and Sporadic AD 
 Familial AD runs in families (copies of one or two genes inherited from an 
individual’s parents) and sporadic AD or nonfamilial AD has no inheritance pattern of 
mutated genes like that of familial AD (Alzheimer’s Association, 2016). EOAD may be 
either familial or sporadic and may be caused by mutations in three genes: amyloid 
precursor protein (APP), presenilin 1 (PSEN1), and presenilin 2 (PSEN2), which are 
located on three chromosomes (Bagyinszky, Youn, An, & Kim, 2014). Mutations in the 
APP gene will cause an abnormal form of amyloid protein to be produced. Mutations in 
the PSEN1 gene will cause an abnormal presenilin 1 protein to be produced. Mutations in 
the PSEN2 gene will case an abnormal presenilin 2 protein to be produced (Bagyinsky et 
al., 2014). 
 According to the National Institute of Health, amyloid precursor protein (APP) is 
found in the brain and is believed to play a role in neuron formation (NIH, 2014). 
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Presenilin proteins help to process amyloid proteins by cutting them into smaller 
segments or peptides with the help of other enzymes (Bagyinsky et al., 2014): However 
when mutations of the presenilin genes occur, this disrupts the processing of the amyloid 
precursor protein, causing overproduction of amyloid-β peptide (Bagyinsky et al., 2014). 
This protein fragment can build up in the brain and cause formation of clumps, called 
amyloid plaques, with the end result likely leading to neuronal death and to progressive 
signs and symptoms of AD (Bagyinsky et al., 2014; Kar et al., 2004). 
 Point mutations in the gene for amyloid precursor protein (APP) on chromosome 
21 have been associated with early-onset (< 65 years) familial AD cases (Yu et al., 2013). 
On the other hand, many early onset cases have been linked to alterations in 2 other 
genes: PSEN1 on chromosome 14, where most AD risk factor mutations have been 
detected; and PSEN2 on chromosome 1. Mutations of these three genes can account for 
30%-50% of all autosomal dominant early onset cases (Kar et al., 2004).  
Late onset AD (LOAD)/Apolipoprotein E 
 Bagyinszky et al. (2014) stated that the apolipoprotein E (APOE) gene is inherited 
and is an important genetic risk factor for LOAD. Apolipoprotein E is a major cholesterol 
carrier in the brain and can be involved in the repair and maintenance of neurons 
(Bagyinsky et al., 2014).  There are at least three variations of the APOE gene, which 
consist of ε2, ε3, and ε4 alleles.  The ε4 allele of the APOE gene, on chromosome 19, has 
been linked with a significant high risk for late-onset of AD (Bagyinsky et al., 2014; 
Brainerd et al., 2013).  Kar et al. (2004) explained that having a single copy of the ε4 
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allele can increase the chances of inheriting or developing AD 2 to 5 times, but having 
two ε4 alleles can raise the chances to more than 5 times. Bagyinsky et al. (2014) report 
that ε3 is the most common APOE gene found in the general population. Both ε2 and ε3 
may participate in neuronal repair and maintenance. The ε2 allele, on the other hand, 
protects against developing AD (Bagyinsky et al., 2014; Kar et al., 2004). Both ε2 and ε4 
alleles have been associated with chromosome 19. Nonetheless, Kar et al. (2004) 
determined that none of the AD cases in their sample were associated with any of these 
genes.  
 Recent postmortem research (Yu et al., 2013) was conducted on participants 
(N=581) who came from two longitudinal clinical-pathological studies, the Religious 
Orders Study (ROS) and the Memory and Aging Project (MAP). The authors’ goal was 
to test the hypothesis of an association of APOE ε4 allele with cognitive decline. 
Participants underwent cognitive performance evaluations annually for 18 years prior to 
death. Assessments provided objective evidence suggesting that ε4 is an important 
determinant of late-life change in cognition (including terminal decline) and may 
contribute to AD pathology (Yu et al., 2013). There still remains controversy concerning 
whether ε4 is a risk factor in the transition from mild cognitive impairment to AD 
(Brainerd et al., 2013).  
 Neurofibrillary tangles are abundant in the brains of individuals with AD, 
especially in the entorhinal cortex, hippocampus, amygdala, association cortices of the 
frontal, temporal, and parietal lobes, and certain subcortical regions projecting to these 
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regions (Kar, Slowikowski, Westaway, & Howard, 2004). Neurofibrillary tangles are 
composed of paired helical filaments (PHF) and sometimes single straight filaments 
containing an abnormal hyperphosphorylated form of the microtubule-associated protein 
tau. PHF formation reduces the ability of tau to stabilize microtubules which leads to 
neuronal transport disruption and eventually to the death of affected neurons. The degree 
of neurofibrillary pathology, and specifically the amount of cortical neurofibrillary 
tangles, positively correlates with the severity of dementia (Kar et al., 2004). 
 Yu et al. (2013) stated that neuritic plaques are multicellular lesions containing 
amyloid peptide deposits surrounded by dystrophic neuritis, reactive astrocytes, and 
activated microglia. The main amyloid peptides found in the plaques are β-amyloid1-42 
(Aβ1-42) and Aβ1-40p peptides that are generated by proteolytic cleavage of APP. Aβ1-42 is 
deposited first and is the predominant form in senile plaques, but Aβ1-40 is deposited later 
on during progression of AD. Evidence suggests that Aβ peptide accumulation in the 
brain, over time, initiates or contributes to AD pathogenesis (Kar et al., 2004; Yu et al., 
2013). Overproduction or reduced clearance, or both, of Aβ peptides are likely key to 
amyloid aggregation. This in turn adds to neurofibrillary tangle development and 
subsequent neuronal degeneration. Research studies of adult animals and of APP 
transgenic mice demonstrate that injection of aggregated Aβ induces neuronal loss in 
selected regions of the brain (Kar et al., 2004; Yu et al., 2013). 
 Vloeberghs, Van Dam, Coen, Staufenbiel, and De Deyn (2006) conducted in vivo 
research involving APP23 transgenic mouse models, which are valuable animal models 
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of AD. These researchers suggested that transgenic mice models mimic memory deficits 
as well as several devastating behavioral disturbances of demented patients. These 
transgenic mouse models approximate the clinical situation and are able to provide an 
instrument to evaluate diverse therapeutic interventions (Vloeberghs et al., 2006). Aβ 
injection peptide can increase formation of neurofibrillary tangles in tau transgenic mice 
(Vloeberghs et al., 2006). Evidence of this relation was initially observed in family 
members with familial AD. Although results suggest that Aβ peptides play a role in the 
neurodegenerative process, both the role they play in the brain and the means by which 
they cause neuronal loss and tau abnormalities in AD are poorly understood (Kar, 
Slowikowski, Westaway, & Howard, 2004).  
Who is affected by Alzheimer’s disease? 
 Individuals affected by AD experience a variety of symptoms that can ultimately 
lead to death. The healthcare system, the government, academia, and scientific 
communities, as well as family members and caregivers are also affected by the effects of 
this degenerative disorder (Delavande, Hurd, Martovell, & Langa, 2013; Reuben, 2007; 
Stefanacci, 2008).  The baby boomers will comprise about 10 million individuals who 
will contract the disease over the next decade. With this in mind, the healthcare system as 
well as the government will need to understand and prepare for the impact this will have 
on future spending, medical and psychological treatment, outcomes, and prevention 
measures (Furiak et al., 2012; Mielke et al., 2012; Naylor et al., 2012; Wimo, Jonson, 
Bond, Prince, & Winblad, 2013). In 2012, the estimated cost of treatment for Alzheimer’s 
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patients was $200 billion (Okie, 2011). There are also roughly 10 million unpaid 
caregivers who are currently assisting individuals who have been diagnosed with the 
disease.  
Brain Functions and Structures 
 Postmortem studies on AD have focused on some of the brain structures involved 
in memory, such as the hippocampus (Nadel & Peterson, 2013; Yu et al., 2013). 
Examinations of AD patients have also identified some of the microscopic aberrations 
associated with the disease process (unique tangled fibers and plaques in the brain tissue). 
Even though lesion techniques provide a basic foundation for understanding the brain’s 
relationship to behavior, these techniques are limited because they cannot be performed 
on the living human brain (Kar, Slowikowski, Westaway, & Howard, 2004). 
 If scientists want to understand physiological processes and functions of the brain, 
they have to use in vivo research, which is performed solely on animals (Vloebergs, Van 
Dam, Coen, Staufenbiel, & De Deyn, 2006). Early in vivo research consisted of inserting 
microelectrodes into the brain of an animal (i.e., a cat, mouse, or a monkey) in order to 
obtain a single-cell recording of a single neuron in the brain. In humans, Langeslag and 
van Strien (2009) revealed how the brain is being studied by using electrical analyses 
(e.g., electroencephalograms and event-related potentials), X-ray techniques (e.g., 
angiograms and computer tomograms) and magnetic field computer analyses within the 
brain (magnetic resonance imaging). Taylor, Rastle, and Davis (2013) conducted a 
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similar study showing blood flow and metabolism computer analysis within the brain 
(positron emission tomography and functional magnetic resonance imaging).  
 Yerokhim et al. (2012) conducted a pilot study demonstrating the benefits of 
exercise on memory and cognition using EEG and ERP. Currently, none of these 
techniques provides definite mappings of exact functions to particular brain structures, 
regions, or processes (Baxter & Bucci, 2013; Brainerd et al., 2013; Yu et al., 2013). 
However, some discrete brain structures, regions, or processes have been found to be 
involved in particular cognitive functions (Nadel & Peterson, 2013). Thus, present 
understanding of this involvement allows only correlational evidence of some type of 
relationship. Sophisticated analyses can highlight increasingly precise relationships, but 
research is not at the point where a specific cause-effect relationship between a given 
brain structure or process and a particular cognitive function can be determined. Lastly, 
the above techniques provide the best information only in combination with other 
experimental techniques for understanding cognitive functioning complexities (Baxter & 
Bucci, 2013; Brainerd et al., 2013; Yu et al., 2013). 
Brain Regions 
 The brain is part of the nervous system and can be viewed as being divided into 
three major regions: forebrain, midbrain, and hindbrain (Sternberg, 2009). The forebrain 
is the region located toward the top and front of the brain and contains the cerebral 
cortex, the basal ganglia, the limbic system, the thalamus, and the hypothalamus. The 
limbic system is important to emotion, motivation, memory, and learning.  Therefore, the 
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limbic system is important to Alzheimer’s disease, especially if memory is distorted or 
impaired. MacDuffie et al. (2012) posited that memory distortion in AD is a clinically 
relevant concern. AD patients and their caregivers frequently report incidents of getting 
lost, misplacing possessions, and confusing present experiences with past ones. The 
limbic system allows individuals to better adapt to a changing environment. It comprises 
three central interconnected cerebral structures, which includes the amygdale, the septum, 
and the hippocampus (Sternberg, 2009).  
 Wolk and Dickerson (2011) indicated that the medial temporal lobes (MTL), 
particularly the hippocampus, play a central role in episodic memory function. The most 
profound forms of amnesia are associated with damage to these brain structures. 
Alzheimer’s disease is the most common form of acquired amnesia (Wolf & Dickerson, 
2011).  Given the involvement of neuropathology, specifically neurofibrillary tangles in 
the medial temporal lobes (MTL) of AD patients, much of the work examining AD 
memory impairment has focused attention on the hippocampus and other structures of the 
MTL (Wolk & Dickerson, 2011). 
 The hippocampus is a structure within the limbic system (Nadel & Peterson, 
2013). The hippocampus and nearby cerebral structures are important for explicit 
memory of experiences and other declarative information. The hippocampus also plays a 
key role in declarative information encoding. According to Nadel and Peterson (2013), it 
is involved in the transfer of newly synthesized information into long-term structures 
supporting declarative knowledge. The basal ganglia are memory structures responsible 
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for nondeclarative memory forms. These structures are primary in controlling procedural 
knowledge, one form of nondeclarative memory (Willems, Salmon, & Van der Linden, 
2008).  
Memory Processes 
 Memory loss, memory impairment, and memory distortion, as well as impairment 
in thinking, are core features of AD (MacDuffie et al., 2013). Therefore, a general review 
of memory processes can be useful in understanding these specific memory symptoms in 
AD.  
 Memory is the means by which individuals retain and draw on prior experiences 
in order to function in the present. It is the ability of the brain to store and access learned 
experiences (Sternberg, 2009). Memory and learning are two ways of thinking about the 
same thing. Each of these processes deals with the brain’s ability to change in response to 
experience. Memory allows changes of the brain to be stored and then reactivated (Pinel, 
2009).  
 MacDuffie et al. (2013) conducted a study on memory distortions comparing 
performance of mild-to-moderate AD patients to that of aged-matched, healthy older 
adult participants on short-term memory (STM) and long-term memory (LTM) tasks. 
Participants were tested on the STM version of the Deese-Roediger-McDermott (DRM) 
task to measure recall memory for four-word lists and were tested on the LTM version of 
the DRM task to measure recall memory for 12-word lists. AD participants showed 
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greater impairment on the LTM task than the STM task. Authors concluded that STM 
impairment with some preserved semantic process is evident in AD. 
 Memory is the capacity for storing and retrieving information. Encoding, storage, 
and retrieval are the three processes involved in memory. These three processes 
contribute to whether information is remembered or forgotten (Sternberg, 2009). 
Encoding 
 Vermeulin, Chang, Mermillow, Pleyers, and Corneille (2013) agreed that 
processing information into memory is called encoding. There are several ways of 
encoding information verbally. Structural encoding entails focusing on what words look 
like; phonemic encoding entails focusing on the sound of words; and semantic encoding 
entails focusing on the meaning of words. Castle, Balota, and McCabe (2009) focused on 
encoding, implying that older adults perform poorer on tasks involving executive 
processes, working memory and frontal lobe functions, leading to difficulties on tasks 
such as attention and memory. Hence, examination of attention control impairments and 
behavioral development measures can serve as useful early diagnostic measures of AD. 
Storage 
 After information enters the brain it is stored. Atkinson and Shiffrin (1968) 
proposed the three-stage model used to describe the storage process. This model 
indicated that information is stored in three memory systems (sensory memory, short-
term memory, and long-term memory) sequentially.  
33 
 
 Sensory memory. Winkler and Cowan (2005) explained that sensory memory 
stores information which is received through sense organs, but only for an instant. The 
information is unprocessed, but sensory memory capacity is very large. Information is 
sometimes transferred from sensory memory into short-term memory (STM), which 
holds information for about 20 seconds. However if this information is rehearsed it can 
stay within STM between 15 and 30 seconds. Rehearsal of information in STM can be 
accomplished by repeating items verbally (Winker & Cowan, 2005).  
 Short-term memory/working memory. Vermeulen, Chang, Mermillod, Pleyers, 
and Corneille (2013) and other researchers referred to short-term memory as working 
memory. Instead of referring to it as a temporary information storage system, working 
memory is an active system used to manipulate information. It holds information 
individuals are consciously thinking about in the present, i.e., processes like adding and 
subtracting, problem solving, thinking about the meaning of what is heard or read, or 
carrying out a sequence of operations. Working memory holds information that is derived 
from sensory inputs or retrieved from long-term memory (Vermeulen et al., 2013).  
 The concept of working memory was first introduced by Baddeley and Hitch 
(1974). The authors proposed that short-term memory be reformulated as a working 
memory that could perform a number of different functions. Baddeley and Hitch (1974) 
believed that Atkinson’s and Shiffrin’s (1968) short-term memory described in the multi-
store model was too simple. The model depicted STM as a single system or store without 
any subsystems. Baddeley and Hitch (1974) indicated that working memory is short-term 
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memory, but instead of information going into one single system, there exist different 
systems for different types of information. The authors suggested that working memory 
consists of a central executive that controls and coordinates operation of the phonological 
loop and the visuo-spatial sketch pad, which are two subsystems. The central executive 
directs the memory system and allocates data and resources to the two subsystems. The 
visuo-spatial sketchpad is used for navigation and stores and processes information in a 
visual or spatial form. The phonological loop is responsible for manipulation of speech-
based information and deals with written and spoken material. 
 Long-term memory. Winkler and Cowan (2005) indicated that information can 
be transferred from short-term/working memory to long-term memory (LTM) and vice 
versa. LTM may store information for a lifetime and it may have an infinite amount of 
capacity. However, because information stays in an individual’s LTM does not mean that 
the information will be readily or easily retrieved (Winkler & Cowan, 2005). Retrieval is 
the process of getting information out of long-term memory and into short-term or 
working memory. The brain organizes information by category in LTM. Another way 
information is organized in LTM is by connection to other information, relevance, and 
familiarity. Tulving (1972) proposed subdivisions of long-term memory, e.g., explicit 
memory, which involves episodic and semantic memory, and implicit memory which 
involves procedural memory. 
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Explicit and Implicit Memory 
 Learning changes the brain and memory refers to the storage and retrieval of 
information of these changes (Pinel, 2009). Memory includes both explicit and implicit 
memory, which are two functionally and anatomically separable long-term memory 
systems in humans (Pinel, 2009).  Long-term memory stores a lifetime of information 
and allows the retention of physical skills and word meanings that have been learned. 
Experts and research psychologists that gain insight into memory from amnesia victims 
are able to distinguish between explicit and implicit memories (Eakin & Smith, 2012; 
Tulving & Schacter, 1990; Willems, Salmon, & Van der Linden, 2008).  As a result, 
amnesia patients have been studied to gain valuable insight into memory functioning in 
general. 
Explicit Memory: Episodic and Semantic 
 Gold and Budson (2008) posited that explicit memory, also referred to as 
declarative memory,  is the intentional memory or conscious recollections of facts and 
events gained from past experiences (e.g., cooking, driving to work, and using the 
computer). Explicit memory is also referred to as declarative memory because it can be 
remembered and described in words (Tulving & Schacter, 1990). Older individuals often 
experience problems with explicit memory (Ward, Berry, & Shanks, 2013). 
 Lah and Smith (2014) reported differential relations between two varieties of 
explicit long-term memories: episodic and semantic memories. These authors conclude 
that children with semantic memory impairments who experience medial temporal lobe 
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epilepsy have problems with reading comprehension, spelling, and reading accuracy. 
However, children with episodic memory impairments do not experience any problems in 
reading comprehension, but do have disturbance in spelling and reading accuracy (Lah & 
Smith, 2014). As in AD, these children do not have the ability to store new information, 
which would be the case of spelling and reading accuracy that involves new meaning of 
words and being able to spell new words. Glosser, Friedmand, and Grugan (1999) 
conducted a study on 21 AD patients and 27 matched controls to understand why AD 
patients performed slightly below controls on all reading and spelling tasks. The authors 
concluded that the mild alexia and agraphia in AD reflected semantic deficits and 
nonlinguistic impairments, which occur in patients with focal lesions in the left 
hemisphere.  
In other words, Glosser et al. (1999) explained that:  
 “basic orthographic and phonological knowledge that relies on procedural 
 integrity mediated by the regions within the left, language-dominant 
 cerebral hemisphere remain  intact through the middle stages of AD. However, 
 lexical-semantic, episodic, and working memory functions that are  subserved by a 
 more distributed cerebral network become impaired in the early stages of AD. 
 This can result in oral and written language  disturbance seen in individuals with 
 probable AD,” p. 357. 
 Episodic memory. Gold and Budson (2008) suggested that there are six cognitive 
domains that are commonly disturbed in individuals suffering from AD. They include 
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memory, language, executive functioning, visuospatial functioning, affect, and attention. 
Memory impairment is the central problem of all the disturbances. Memory problems are 
also one of the main reasons for admission to residential nursing facilities. A longitudinal 
study reported that annual savings of $4 billion could be achieved by delaying the onset 
of nursing home care by 1 month for elderly adults with dementia illnesses (Gold & 
Budson, 2008). Knowledge of the specific memorial processes that are impaired in AD 
may be important to researchers and scientists developing therapies and assessing the 
efficacy of those therapies. Gold and Budson (2008) characterized AD as a progressive 
neurodegenerative disease manifested by cognitive disturbances, the earliest and most 
prominent being impaired episodic memory.  
 Episodic memory is a form of explicit memory that is most affected by amnesia 
(Pinel, 2009; Wolk & Dickerson, 2011).Episodic memory is a part of long-term memory, 
which involves conscious thought and is declarative. Episodic memory also involves 
storing information about events or episodes that have occurred throughout an 
individual’s life (McLeod, 2010).   
 A number of episodic memory measures involving verbal list learning tasks have 
been used to diagnose and monitor disease progression in AD (Wolk & Dickerson, 2011). 
Immediate recall, delayed free recall, and recognition memory are memory measures 
often assessed using verbal list learning tasks. However, there is a major debate in 
memory literature of whether recollection is differently represented in the MTL relative 
to familiarity (Wolk & Dickerson, 2011).  Serra et al. (2010) explained that recollection 
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and familiarity are two types of processes involved in episodic memory recognition. 
Serra et al. (2010) stated that “recollection is the conscious re-experience of a previous 
event, and familiarity is the feeling of having previously encountered a stimulus with no 
associated contextual information,” p. 316. 
Individuals with amnesic mild cognitive impairment (a-MCI) had an increased 
risk of developing Alzheimer’s disease (Serra et al., 2010). Previous studies have 
established characteristic episodic memory impairment in a-MCI, with early recognition 
dysfunction. Serra et al. (2010) conducted a study on 19 patients who had been diagnosed 
with a-MCI and compared them with 23 healthy patients who were matched for sex, age, 
and education The authors used the process dissociation procedure (PDP) and the 
remember/know (R/K) procedure to assess whether the patient group recognition deficits 
were due to recollection selective impairment rather than familiarity. Both procedural 
results revealed selective preservation of familiarity in a-MCI patients. During the study 
phase of the R/K procedure, MCI-patients showed significant recollection impairment for 
words that were anagrammed or read. Serra et al. (2010) hypothesized recollection and 
familiarity as being independent processes coupled with different anatomical substrates. 
 Semantic memory. Semantic memory is also a form of explicit memory and it is 
an accumulation of factual knowledge, but it is not usually affected by amnesia. 
However, semantic memory is affected by AD (Pinel, 2009; Wolk & Dickerson, 2011). 
Perri, Zannino, Caltagirone, and Carlesino (2012) further discussed distinctions of long-
term memory. Semantic memory is another part of long-term memory that also involves 
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conscious thought and is declarative. This part of long-term memory includes knowledge 
about word meaning as well as general knowledge. Semantic memory is also responsible 
for storing information about the world. In a disease stage of AD, the authors explain that 
patients may not be able to name objects or describe the semantic characteristics of 
concepts. However, they may still possess the ability to produce superordinate category 
names of objects or place them in the correct semantic category (Perri et al., 2012). 
Implicit Memory: Procedural Memory 
 Implicit memory, referred to as nondeclarative memory, is the unintentional 
memory or unconscious recollections of facts and events gained from past experiences 
(Tulving & Schacter, 1990).  Generally, implicit memory is not affected by age (Ward, 
Berry, & Shanks, 2013). Facets of implicit memory appear to remain intact in AD victims 
through final disease stages until death. 
Procedural memory. Procedural memory is a form of implicit memory (long-
term memory), which involves knowing how to do things such as memory of motor 
skills; it is not generally affected by AD (Tulving & Schacter, 1990). This nondeclarative 
act, procedural memory, does not involve consciousness, and it is an automatic response. 
Knowing how to ride a bike is an example of procedural memory (Willems, Salmon, & 
Van der Linden, 2008). Distinction between procedural and declarative memory came 
from research on patients with amnesia (Gobel et al., 2013). Procedural memory and 
emotional responses are two forms of nondeclarative memory. Procedural memory, 
associated with some forms of semantic memory, is not affected by amnesia or damage to 
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the hippocampus (Willems et al., 2008). However, it is affected by damage to the 
cerebellum or disorders that alter the basal ganglia (Gobel et al., 2013). The cerebellum is 
most connected to working memory and its adaptive models of working memory 
processing are fed back to the frontal lobe for control processes. It allows for the mental 
manipulation of information during memory encoding (Gobel et al., 2013). Emotional 
responses are intense personal memories that have close association with the amygdala, 
which manages fear reactions. Both the amygdala and the hippocampus have close 
association with each other and each plays key roles in traumatic experiences that 
provoke anxiety (Willems et al., 2008). 
 Implicit habit learning is not linked to higher level cortical association because 
AD patients perform normally on implicit habit learning tests, confirming that habit 
learning does not rely on explicit memory and the MTL brain regions that subserve 
explicit memory (Eakin & Smith, 2012). This information supported other studies (Gobel 
et al., 2013; Wilkinson et al., 2011) confirming that the basal ganglia played a key role in 
implicit habit learning of AD patients. However, there are other researchers who 
disagreed and believed that working memory mechanisms were the reasons AD patients 
performed normally on implicit habit learning tests (Nosofsky et al., 2012; Smith, 2008).  
 Implicit skill learning depends on nondeclarative memory that operates 
independent of the MTL memory system and, instead, depends on corticostriatal circuits 
between the basal ganglia and cortical areas supporting motor function and planning 
(Gobel et al., 2013).  Basal ganglia are a collection of nuclei deep to the white matter of 
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cerebral cortex, which are inhibitory. The function of the basal ganglia is complex and 
contributes to some of the subconscious aspects of voluntary movement such as 
inhibiting tremor and accessory movements (Wilkinson, Khan, & Jahanshahi, 2009).   
 The basal ganglia do not initiate movement, but contribute to complex motor 
circuit coordination (Wilkinson et al., 2009). This region of the brain is associated with 
four neurotransmitters: acetylcholine, dopamine, gamma-aminobutyric acid (GABA), and 
serotonin (Pinel, 2009). Acetylcholine levels are greatly reduced in AD patients. The 
reduction in acetylcholine is the result of degeneration of the basal forebrain, which is a 
midline area located above the hypothalamus (Pinel, 2009). Neurotransmitters and 
modulators such as acetylcholine (ACh), serotonin, noradrenaline and somatostatin were 
altered in patients with AD. Karr, Slowikowski, Westaway and Mount (2004) indicated 
that the amount of activity of the ACh-synthesizing enzyme, choline acetyl-transferase 
(ChAT) in the neocortex was significantly decreased, correlating positively with the 
severity of dementia. Decreased choline uptake, and ACh release and cholinergic 
neuronal loss from the region of the basal forebrain further indicated a selective 
presynaptic cholinergic deficit in the hippocampus and neocortex of the brains of 
individuals with AD. 
 Acetylcholine also appeared to enhance neural transmission associated with 
memory (Hartig et al., 2014; Kar et al., 2004). High concentrations of acetylcholine were 
found in the hippocampus of normal people and low concentrations of this 
neurotransmitter were found in individuals with Alzheimer’s disease. Moreover, AD 
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patients showed severe loss of brain tissue that secreted acetylcholine. Croxson et al. 
(2012) explained that acetylcholine had been implicated in episodic memory, which was 
damaged in AD. Acetylcholinesterase inhibitors (AChEIs) such as donepezil, 
galantamine, and rivastigmine work by raising ACh levels and has demonstrated 
significant symptomatic efficacy in AD (Parsons et al., 2013).  
The three AChEI’s underlying mechanisms were distinguished by target protein 
specificity (Parsons et al., 2013). Donepezil independently has interacted with neuronal 
nicotinic Ach receptors and is a specific reversible inhibitor of AChE. Rivastigmine, in 
contrast, is a pseudo-irreversible AChE inhibitor. Rivastigmine has a similar affinity level 
for butyrylcholinesterase (BuChE), which is a non-specific enzyme that hydrolyses ACh 
and other cholinesters, which are predominantly outside the CNS, with brain levels that 
have increased to severe AD. Galantamine has a potential link to amyloid-beta clearance. 
This AChEI is a selective, reversible inhibitor, which enhances intrinsic ACh action on 
nicotinic receptors (Parsons et al., 2013). AChEIs have proven to slow cognitive decline, 
although there is lack of memory improvement. Croxson et al. (2012) suggested that this 
was due to acetylcholine having a possible role in boosting attentional performance or 
cortical function.  
Symptoms and Stages of Alzheimer’s Disease 
 AD is characterized by the onset of impairments in memory and executive 
function, in addition to cognitive and behavioral problems, such as depression, apathy, 
and agitation (Wilson, Arnold, Beck, Bienias, & Bennett, 2008). AD patients have been 
43 
 
known to have different symptoms at different stages of the disease. It is also hard to 
place individuals in any one stage of AD because the stages can sometimes overlap (AA, 
2013).  
 Dr. Barry Reisberg at the New York University School of Medicine’s Sillberstein 
Aging and Dementia Research Center developed a seven-stage framework for AD (see 
Appendix B). He indicated that not everyone who develops the disease will have the 
exact symptoms, or the same rate of progression (AA, 2013).  
Risk Factors for Alzheimer’s disease 
 Age and sex are consistent risk factors for Alzheimer’s disease (Kalaria et al., 
2008; Perez et al., 2012). Most individuals who have been diagnosed with AD are 65-
years-plus (LOAD) and are women. They often experience low literacy, which is linked 
to poverty or lower socioeconomic status, leading to poor health, and lower access to 
healthcare. According to prevalence studies such as the Chicago Health and Aging 
Project (CHAP) and the Aging Demographics and Memory Study (ADAMS) 
approximately two-thirds of Americans with AD are women. Of the 5.2 million older 
than 65 years with AD in America, 3.4 million are women and 1.8 million are men.  The 
ADAMS study revealed that 16% of females over 71 years of age have AD compared to 
11% of males (AA, 2013).  
 Other risk factors include genetic association and risk genes--many times family 
members of the diagnosed AD patient have more likelihood of inheriting a predisposition 
or vulnerability to the disease as well. The gene Apolipoprotein E (APOE ε4 allele) and  
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the gene SORL1 are also risk factors for AD and they are usually linked to older women 
who have been diagnosed with LOAD (Brainerd, Reyna, Petersen, Smith, & Taub, 2011). 
For example, the gene APOE ε4 allele is apparently linked to specific decreases in AD 
patients’ functional connectivity, according to EEG coherence studies. Other risk factors 
that are associated with AD include stroke injuries, vascular diseases, type 2 diabetes, 
obesity, hypertension, and decreased physical activity (Bassil & Grossberg, 2010; Mathis 
& Burke, 2009; Solfrizzi, et al., 2013). 
Diagnosis of Alzheimer’s Disease 
 Handen et al. (2012) agreed with research that a definitive diagnosis of AD cannot 
be made until the death of an individual. It depends on the identification of amyloid 
plaques and neurofibrillary tangles at brain autopsy.  Deposition of amyloid usually 
begins about 10 years prior to clinical symptoms (Handen et al., 2012). This finding is 
usually accomplished with the help of brain imaging, e.g., positron emission tomography 
(PET). Brain damage associated with AD also includes many regions of the brain that 
perform significant memory functions such as the medial temporal lobe and the prefrontal 
cortex. 
 The Alzheimer’s Association Report (AA, 2013) indicated that a diagnosis of AD 
is usually made by a primary care physician (PCP). This individual often obtains medical 
and family history comprising psychiatric history and cognitive and behavioral changes. 
The PCP will also ask family members or caregivers about the AD patient to gain input. 
Additionally, the PCP will conduct cognitive, physical, and neurological examinations, 
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and will often have the patient undergo MRI to help identify brain changes (Mathis & 
Burke, 2009). The MRI helps to detect such brain changes as strokes or tumors that can 
explain the individual’s symptoms. In 2011, new criteria and guidelines were proposed 
by the NIA and the Alzheimer’s Association for the diagnosis of AD, which are updated 
diagnostic criteria and guidelines proposed in 1984 by the Alzheimer’s Association and 
the National Institute of Neurological Disorders and Stroke (AA, 2013; NIA, 2013).  
 Thomas and Fenech (2007) conducted a review on genome mutation and AD, 
which is similar to memory profiling; this is helpful in identifying MCI cases that will 
eventually progress into AD. These authors proposed that AD patients could be clinically 
diagnosed with an approximate accuracy between 60 and 70%, based on cognitive 
impairment and behavioral change criteria. The criteria were based on the National 
Institute of Neurological and Communicative Disorders and Stroke-Alzheimer’s Disease 
and related Disorders Association (NINCDS-AD & DA), which are still measured by the 
mini-mental state examination (MMSE). This examination allows a quantitative measure 
of cognition status to be conducted (AA, 2013; Almkvist & Tallberg, 2009). 
Screening for Alzheimer’s disease 
 The Centers for Medicare and Medicaid Service (CMS) recommended assessment 
tools for the detection of cognitive impairment (Cordell et al., 2013; Dowling, Herman, 
La Rue, & Sager, 2010; Kawas et al., 2013). The Alzheimer’s Association convened to 
develop an expert group (Alzheimer’s Association Medicare Annual Wellness Visit 
Algorithm for Assessment of Cognition) that would provide recommendations to primary 
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care physicians in the screening and detection of dementia to reduce the prevalence of 
delayed or missed diagnosis. The patient or informant to be screened would be observed 
by the primary care physician. The PCP would then review Health Risk Assessment 
information, conduct unstructured queries during the annual wellness visit (AWV), and 
utilize structured cognitive assessment tools. This recommendation was due in part to a 
number of studies supporting the fact that 27%-81% of patients in primary care who are 
affected with cognitive impairment go unrecognized/undiagnosed (Cordell et al., 2013).  
 Although there is growing attention among developed nations concerning 
medical, emotional, social, and financial burdens of Alzheimer’s disease, there is no 
definite answer of whether or not screening is beneficial compared to its costs (Furiak, 
2012).  Nonetheless, most agree that if screening is done early on with patients who have 
the potential or high risk of developing dementia/AD, both patients and caregivers can 
initiate planning, organize ongoing care, prepare for long-term planning for both social 
and financial well-being, prepare to have care-giving training, plan for stress 
management, or rule out dementia early on in order to search for alternative symptom 
causes. As a result, treatment can begin much sooner, whether it is pharmacological or 
non-pharmacological (Borson et al., 2013; Furiak et al., 2012). 
Treatment/Prolongation of Alzheimer’s disease 
Non-pharmacological Therapy 
 Treatment of AD consists of both non-pharmacological and pharmacological 
therapy models. The non-pharmacological therapy model is usually conducted by trained 
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professionals (i.e., psychiatrists, psychologists, or master-level clinicians), who follow 
practice guidelines recommended by the APA, which put emphasis on neuropsychiatric, 
psychiatric, and behavioral symptoms. Logsdon, McCurry, and Teri (2007) focused on 
using evidence-based psychological treatments (EBTs) for dementia patients with 
behavioral disturbances. Kazdin (2011) suggested that EBTs are the interventions 
carefully evaluated in research. Evidence-based practice is a broader term. It refers to the 
clinical practice that is informed by evidence about interventions, clinical experience, and 
patient needs, values, and preferences and their integration to make decisions about 
individual care.  
 The American Psychological Association (APA) Task force set criteria for EBTs 
for psychological disorders, which have specific coding criteria (APA, 2007). The criteria 
specified that studies have to treat the same symptom, target problem, or diagnosis. 
Logsdon et al. (2007) used predetermined behavioral disturbance levels as an eligibility 
requirement. Treatment interventions involved the progressively lowered stress threshold 
(PLST) theoretical framework for outcomes between treatment and control groups. The 
protocol was based on a behavioral problem solving theoretical framework.  
 Logsdon et al. (2007) discussed three studies, which are collectively known as 
The Seattle Protocol. The first study included patients who were diagnosed with dementia 
and depression. The goal of the intervention was to decrease depressive behaviors and 
increase pleasant events. In the second study, the intervention was combined with a 
home-based program to decrease behavioral disturbances and improve participants’ 
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physical function. For the third study, the intervention goal was to improve patient 
caregivers’ well-being and decrease behavioral disturbances (Logsdon et al., 2007). 
 Logsdon et al. (2007) pointed out that results using the PLST indicate that all 
psychological interventions appear most effective when behavioral problem solving is 
provided by or supervised directly by clinical professionals who have expertise in both 
behavior therapy and dementia care. Next, psychological interventions that meet EBT 
criteria work most effectively with patients with anxious or depressive behaviors. More 
research is required to prove EBT’s efficacy with patients who are severely agitated. 
Lastly, behavioral disturbances appear less often in early stage dementia patients than 
they do in patients at the late stage or progression of the disease.  
 Logsdon et al. (2007) also noted that the progressive worsening of cognitive 
impairment in individuals with dementia has proven to be a challenge when applying 
EBT criteria to interventions for behavioral disturbances. Continual adjustment of 
treatment plans, expectations, and approaches is required depending on the patient and 
the patient’s support system, including the caregiver. Proven efficacy and investigation of 
treatment approaches, such as cognitive behavior therapy, life review, and 
psychodynamic therapy, commonly used with older adults have not been conducted on 
dementia patients who experience behavioral disturbances (Logsdon et al., 2007).  
Pharmacological Therapy 
 Drug delivery to the central nervous system (CNS) is a challenging 
pharmacological therapy in treating Alzheimer’s disease. According to Khawli and 
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Prabhu (2013), the blood-brain barrier (BBB) only allows molecules that have low 
molecular weight to enter the brain via the bloodstream through the transcellular route. 
Khawli and Prabhu (2013) indicated that “less than 10% of therapeutic agents for 
neurological disease enter into clinical trials because of poor brain penetration,” p. 1471.  
Research efforts focused on manipulating drug characteristics or using endogenous 
transporters or receptors at the BBB. This can only be accomplished through better 
understanding of the CNS and the physiology and pathophysiology of the CNS (Khawli 
& Prabhu, 2013).  
 The Alzheimer’s disease Assessment Scale-cognitive subscale (ADAS-cog) is an 
instrument used to measure cognition in clinical trials. The Food and Drug 
Administration (FDA) proposed the use of quantitative disease-drug-trial models such as 
the ADAS-cog in order to improve drug research and product development for 
individuals with AD (Gomeni et al., 2012). The authors posit that it is better to test 
modifying drugs at the earliest stage of AD as well as treat symptoms early on to 
maintain functional capacity of patients. 
 Acetylcholine (ACh) is a small-molecular neurotransmitter, which is created by 
adding an acetyl group to a choline molecule (Baxter & Bucci, 2013). Acetylcholine 
transmits different kinds of messages to different parts of the brain (adjacent cells), which 
are brief and rapid (Pinel, 2009). Enzymes are used to break apart neurotransmitters. 
Baxter and Bucci (2013) indicated that the enzyme acetylcholinesterase is used to break 
down the neurotransmitter acetylcholine. Cholinergic precursors are chemicals used to 
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produce acetylcholine in neurons. Neurons releasing acetylcholine are said to be 
cholinergic (Pinel, 2009). 
 Schatzberg, Cole, and DeBattista (2010) informed that the first drug FDA-
approved to treat AD was tetrahydroaminoacridine (THA; tacrine). This drug was used in 
Australia to reverse drug-induced coma. Tacrine is a central cholinesterase inhibitor that 
was thought to act by raising brain levels of acetylcholine and increasing cholinergic 
brain activity. As a result, it was used to treat AD patients who had mild to moderate 
dementia (Schatzberg, Cole, & DeBattista, 2010). It is rarely used today because it is 
hepatotoxic, which is damaging or destructive to liver cells.  
 Today, the cholinesterase inhibitors (ChEIs) donepezil, galantamine, and 
rivastigmine are used in the treatment of AD from the mild stages. The most common 
side effects are nausea, diarrhea, insomnia, fatigue, muscle cramps, and anorexia 
(Schatzberg et al., 2010). For the moderate stage of AD, the N-methyl-D-aspartate 
(NMDA) receptor antagonist memantine is a well-established mono-therapy (Gauthier & 
Molinuevo, 2013).  Memantine was approved in 2003 to treat the moderate to severe 
stage of AD. This antagonist is thought to mitigate toxicity resulting from increased 
calcium flow into neurons by blocking NMDA receptors (Schatzberg et al., 2010). When 
NMDA receptors are blocked the neurodegenerative effects resulting from lower 
glutamate levels and increased calcium influx in AD are reduced. This drug has been 
quickly adopted in clinical practice because it is benign. In clinical trials, memantine’s 
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rate of side effects is no different than the rate with placebos--side effects may include 
dizziness, confusion, headaches, and hallucinations. 
  Schatzberg et al. (2010) explained that moderate to severe AD patients, who take 
memantine, appear to have more improved cognition and activities of daily living 
(ADLs) than those who take placebos. Importantly, memantine also modestly reduces the 
time that caregivers must spend with an Alzheimer’s patient. In addition, AD patients 
who are already taking donepezil appear to improve when memantine is added to their 
regimen (Schatzberg et al., 2010). ChEIs and memantine have demonstrated symptomatic 
efficacy in several clinical studies. To treat patients at the moderate to severe stage of 
AD, who have lost their capacity for independent everyday living, a combination therapy 
of both non-pharmacological and pharmacological therapy is used (Gauthier & 
Molinuevo, 2013).  
Combination Therapy 
 Gauthier and Molinuevo (2013) explained that AD symptoms become severe over 
a period of years, which decreases the AD patient’s chances to meet physical, mental, and 
daily needs. The authors suggest that combined therapy including both psychotherapy 
and psychopharmacological therapy is necessary in the absence of a cure for AD. Due to 
the fact that the disease may take up to a decade before it manifests itself, it is important 
to seek and use treatments that may provide both immediate and sustained long-term 
effects to slow the rate of clinical decline. Therefore, the use of combination therapy will 
slow the progression of the disease process by treatment mirroring AD-- using 
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cholinesterase inhibitors (ChEIs) such as donepezil, galantamine, and rivastigmine to 
treat mild stages of AD and using the N-methyl-D-aspartate (NMDA) receptor antagonist 
memantine to treat moderate and onward stages of AD (Gauthier & Molinuevo, 2013). 
However, interventions that substantially affect the course of the disease or the quality of 
life of Alzheimer’s patients appear to be some distance away (Schatzberg et al., 2010). 
Summary 
 Alzheimer’s disease (AD) is the sixth leading cause of death in the United States. 
It is the fifth leading cause of death in Americans over the age of 65 (AA, 2012). The 
amyloid hypothesis is the leading theory that explains AD pathogenesis. Accumulation of 
protein in the brain is the initial event in AD--amyloid plaques followed by 
neurofibrillary tangle formation. AD is the most common form of dementia (AA, 2009). 
The disease is degenerative, causing individuals to have memory loss, and changes in 
reasoning, judgment, and behaviors.  
 AD is a disorder that primarily affects individuals 65 and older, individual’s 
families, caregivers, government, third-party insurance agencies, academia, and the 
scientific communities. A collaboration of all entities must come together to find a cure 
or delay the progression of AD (NAPA, 2011). Brain imaging such as MRIs and PETs 
are also helpful in diagnosing patients with AD. In addition, criteria based on the 
NINCDS-AD&DA and use of clinical instruments to measure cognition and behavior 
resulted in an accurate diagnosis for between 60 and 70% of patients having AD (Thomas 
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& Fenech, 2007). However, presently, the only way to definitively diagnosis AD is 
through brain autopsy (Handen et al., 2012). 
 Consistent risk factors for AD are age and sex (Kalaria et al., 2008; Perez et al., 
2012). Most individuals diagnosed with AD are over the age of 65 (LOAD) and are 
women. Prevalence studies such as the Chicago Health and Aging Project (CHAP) and 
the Aging Demographics and Memory Study (ADAMS) revealed that about two-thirds of 
Americans with AD are women. Of the 5.2 million Americans older than 65 years with 
AD, 3.4 million are women and 1.8 million are men. In addition, the ADAMS study 
indicated that 16% of females over 71 years of age have AD compared to 11% of males. 
Other risk factors include genetic association and risk genes such as APOE ε4 and 
SORL1. In addition, stroke injuries, vascular diseases, type 2 diabetes, obesity, 
hypertension, and decreased physical activity are also risk factors for AD (Bassil & 
Grossberg, 2010; Mathis & Burke, 2009; Solfrizzi, et al., 2013). 
 Memory impairments and executive dysfunction are symptoms of AD. 
Individuals will experience cognitive and behavioral problems such as depression, 
agitation, and apathy (Wilson, Arnold, Beck, Bienias, & Bennett, 2008). Each stage of 
the disease can have different symptoms or sometimes the stages will overlap (AA, 
2013). Progression of AD does not consider age chronology. AD victims can experience 
up to seven stages of the disease, starting from Stage 1, involving no impairment to Stage 
7, which can include very severe cognitive impairment (AA, 2013). 
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 The CMS and the AA are agencies that recommend assessment and screening 
tools to medical and clinical professionals for the diagnosis or detection of dementia/AD 
(Furiak, 2012). Most developed nations agree that early screening conducted on patients 
with a high risk potential will allow patients, family members, and caregivers to initiate 
planning and preparation for long-term financial and social well-being to prepare for 
training, stress management, and on-going care (Furiak, 2012). 
 Treatment of AD can be delivered via psychotherapy, pharmaceutical therapy, or 
a combination of both. There is a great deal of collaboration by the government, public, 
and private sectors to find a cure for AD (Gauthier & Molineuvo, 2013; Khawli & 
Prabhu, 2013; Logsdon et al., 2007). The NAPA (2011), which is a research initiative 
implemented by The Obama Administration, spearheaded additional interest and 
awareness of AD and commitments to find a cure. Continual sharing of information and 
financial support from the government and private sectors are necessities headed in the 
right direction to prolong/put an end to the sixth leading cause of death among 65 year 
olds and beyond. In addition, the increasing population of baby boomers will also be at 
risk for contracting AD (AA, 2013), which is another critical reason to compare 
symptoms and stages of EOAD patients to that of LOAD patients. 
 The above occurrences have led researchers to the facts that AD patients can and 
do go through various stages and symptoms of this degenerative disorder (AA, 2013; 
Gauthier & Molinuevo, 2013; Reisberg, 2013; Wilson et al., 2008). There was a gap in 
literature that did not focus on caregiver perspectives of what they viewed when caring 
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for AD patients while the AD patients were experiencing various stages and symptoms of 
the disease. Chapter 3 focused on research questions, methodology, participant protection 
and rights, instrumentation, and data collection and analysis, which provided a roadmap 
or foundation to explore and determine possible future progress treatment plans, 
incentives and psychological interventions for AD.  
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Chapter 3: Research Method 
Methodology 
AD is defined as development of multiple cognitive deficits evidenced by 
memory impairment or cognitive disturbances that may or may not include the following: 
language disturbance, inability to carry out motor activities, failure to recognize objects, 
or the loss of executive functioning. In addition, these multiple cognitive deficits may or 
may not cause significant impairment in social or occupational functioning and represent 
a significant decline from previous functioning levels (APA, 2013).  
 AD is the fifth leading cause of death among Americans ages 65 and older (AA, 
2012). Although multiple research entities have formed collaborative efforts to prolong 
life with the disease or provide treatment interventions, there is no known cure for AD 
(NAPA, 2011).  
 Over the past 150 years, advances in the treatment of heart disease and cancer 
have contributed to increased life expectancy and a marked change in aging bio-
demographics. In addition, general improvements in public health and medical care 
during the 20
th
 century, such as advances in laboratory techniques and technology, 
investments in disease surveillance, regulation of tobacco products, screening of 
newborns for metabolic and other heritable disorders have added  increased life 
expectancy (Carrillo et al., 2013; CDC, 2011). As a result, the principal causes of death 
have shifted dramatically from chiefly infectious diseases to cardiovascular disease, 
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cancers, and increasingly, progressive neurodegenerative dementias, such as AD (Kling, 
Trojanowski, Wolk, Lee, & Arnold, 2013). 
  AD is the most common form of dementia (AA, 2009). Those commonly 
affected by AD are individuals ranging from age 65 years to 85 years. This group will 
most likely include a significant number of future baby boomers, since they began 
turning 65 in 2011. It has been estimated that by the year 2050 the rising cost to treat this 
population will be $1 trillion or more (Okie, 2011). AD patients have also been known to 
have different symptoms at different stages of the disease. Due to the fact that stages can 
and do overlap, it is hard to place individuals in any one stage of AD (AA, 2013). 
Therefore, comparing symptoms between EOAD patients and LOAD patients offers 
further insight into ways to generate treatment/intervention plans, to slow the progression 
of the disease, or perhaps find a cure for this disorder.  
Research Design and Rationale 
 Chapter 3 described the methodological approach including the mixed-method 
research design, setting, and participants. The mixed-method design was a combination 
of qualitative and quantitative components, including an inductive approach, using 
personal perspectives together with statistical inferences. Chapter 3 also included and 
described instruments used to acquire and analyze data. Process descriptions of ethical 
requirements were presented in this chapter as well. The research questions answered in 
this study were as follows: 
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Research Question and Hypotheses 
RQ1: Are there differences in cognitive symptoms between EOAD patients and LOAD 
patients? 
H01: EOAD patients have the same cognitive symptoms as LOAD patients. 
Ha1: EOAD patients have different cognitive symptoms than LOAD patients. 
RQ2: Are there differences in behavioral symptoms between EOAD patients and LOAD 
patients? 
H02: EOAD patients have the same behavioral symptoms as LOAD patients. 
Ha2: EOAD patients have different behavioral symptoms than LOAD patients. 
Mixed Method Approach 
 A quantitative review was conducted, using a demographic background survey, in 
order to obtain information from caregivers who provided care to AD patients who had 
EOAD or LOAD. These caregivers supplied answers to questions that determined the 
particular stage level of the AD patient.  Quantitative instruments, the BEHAVE-AD 
(Reisberg, et al., 1987) and the Short IQCODE (Jorm, 1994) were used to gain empirical 
evidence of the AD patient’s behavior, which were filled out by the caregiver. A 
qualitative interview preceded caregivers filling out quantitative measures such as the 
BEHAVE-AD and the Short IQCODE. As a result, this research design is both 
quantitative and qualitative in nature, using a sequential mixed method approach.  
Creswell (2009) indicated that quantitative research is a means for testing 
objective theories by examining the relationship among variables. The variables can then 
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be measured, usually on instruments, so that numerical data can be examined utilizing 
statistical processes.  Creswell (2009) defined qualitative research as a means for 
understanding and exploring a social or human problem through the perspectives of 
groups or individuals. The research process involved emerging questions and procedures, 
collecting and analyzing data, building from specific to general themes, and making 
interpretations of data meaning. 
 Storandt, Balota, Aschenbrenner, and Morris (2014) described the clinical, 
cognitive, and personality characteristics of 249 participants in a multinational 
longitudinal study of autosomal dominant Alzheimer’s disease (ADAD). Participants 
were from ADAD families with mutations in 1 of 3 genes (APP, PSEN1, or PSEN2). The 
authors compared cognitively normal mutation carriers, cognitively normal mutation 
noncarriers, and very mildly impaired mutation carriers using mixed model analyses. 
Results revealed that global cognitive deficits like those observed in late-life sporadic AD 
exist in mild ADAD compared with cognitively normal carriers and noncarriers on all but 
two measures of Storandt et al. (2014) concluded that cognitive and personality deficits, 
overall, in very mild ADAD are similar to those seen in sporadic AD and cognitive 
deficits also took place in asymptomatic mutation carriers who were nearer the age of 
dementia onset. 
Participants and Sample Size 
 My introduction to the Alzheimer’s Association was facilitated by the Chief 
Program Director of the Houston Southeast Chapter via letter of cooperation (see 
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Appendix C). This individual provided me access to Alzheimer’s caregiver group 
locations throughout the Houston area and surrounding towns. I distributed flyers 
throughout the Houston Southeast Chapter Alzheimer’s Association locations 
inviting/recruiting caregivers to participate (see Appendix K). I had no relationships with 
the Chief Program Director or any of the Alzheimer’s Association group participants. I 
recruited participants from various caregiver groups, who were members of the 
Alzheimer’s Association, Houston Southeast Chapter, and provided care to individuals 
who had been diagnosed with AD according to criteria in the DSM-V (APA, 2013). The 
study included a qualitative aspect, which consisted of caregivers answering interview 
questions related to operational constructs such as cognitive/behavioral symptoms of AD.  
 Grounded theory was the research tool I used to seek out and understand potential 
social patterns and structures of Alzheimer’s disease through the process of constant 
comparison. Grounded theory generally reflects the participant’s own interpretations or 
coming from their own perspectives, rather than being introduced or imposed by the 
investigator (Coleman, 2006). In qualitative research, the number to reach action or 
grounded theory is between 5 and 20 (Patton, 2001). The process of grounded theory 
involved using multiple stages of data collection and the interrelationship of categorical 
information. I compared data with emerging categories and sampling of different groups 
to maximize the similarities and differences of information. 
 Beard, Sakhtah, Imse, and Galvin (2012) investigated dyads where one spouse 
had been diagnosed with memory loss. The authors conducted in-depth qualitative 
61 
 
interviews with 10 couples (N=20). Beard et al. (2012) used grounded theory approaches 
to collect, code, and analyze data into data themes.  The authors found that community 
services and care practices were insightful to ways that couples organized and prioritized 
their relationship prior to diagnosis in order to encourage positive care patterns between 
them, foster successful adaptation changing needs of the couple, and support in-home 
arrangements for as long as possible. 
 During my research study, the caregivers received a background demographic 
questionnaire from me to complete (See Appendix D) on behalf of the individuals that 
they cared for with AD N = 20. There were two groups for the duration of illness 
comparison and behavioral/cognitive symptoms/changes. Group I (n = 8) consisted of 
EOAD patients (younger than age 65) and Group II (n = 12) consisted of LOAD patients 
(older than age 65). I used demographic survey screening to obtain each group. Preceding 
the quantitative portion of the study, six of the total caregivers received from me a 
qualitative interview to gain their perspectives of what they observed the AD clients 
experiencing in regards to behavioral and cognitive changes. 
Participant Protection and Rights 
 The caregivers were the sole source of information on behalf of the patient sample 
in this study. I explained informed consent and confidentiality to caregivers. They were 
informed that their participation in the research was voluntary, without any 
compensation; and at any time during the research they could withdraw without any form 
of penalty.  I protected the rights of all participants as per certification of the National 
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Institute of Health training course (See Appendix J). In addition, I adhered to questions 
from the standard demographic background questionnaire (See Appendix D), both 
informant questionnaires (See Appendices E and F), a qualitative interview (Appendix G) 
to gain caregiver perspectives of the cognition and behavior of AD clients, and 
caregivers/participants were not coerced in any way through use of personal biases. 
Materials such as questionnaires and statistical instruments were coded with numbers and 
kept in a secured area inside a locked file cabinet. I used email addresses and phone 
numbers to communicate with participants. Once the research study was completed I 
locked all materials and secured them in a locked file cabinet to be kept for 5 years. After 
the 5 years I will destroy the material by shredding it. Upon completion of my study, all 
participants were debriefed via telephone/email. I also provided participants with 
summary results of the study and how it would benefit others living with or caring for 
those with AD in the future. 
Instrumentation 
 Participants were given sufficient information about the study. Once caregivers 
acknowledged that they understood it well enough to make an intelligent decision 
concerning whether or not they wanted to participate, I administered the structured 
demographic questionnaire (see Appendix D) via telephone. If the caregiver had care 
recipients who met criteria as reflected in the demographic questionnaire, then I asked 
them to participate in completing the BEHAVE-AD informant form (see Appendix E) 
and the Short IQCODE (see Appendix F).  I administered the BEHAVE-AD and the 
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Short IQCODE informant instruments via telephone to the caregiver to obtain 
information regarding the individual they were providing care for. I used these 
instruments to assess cognitive, behavioral and general clinical symptoms of the AD 
patient.  I used the BEHAVE-AD and the Short IQCODE assess behavioral and cognitive 
symptoms separately so as not to result in a so-called halo effect, meaning that the rating 
of one area, e.g.: behavioral, can influence rating of another area, e.g.: cognition.  It is 
usually advantageous that assessment of behavioral symptoms and cognitive evaluation 
be separately measured or performed with different instruments in research (Auer, 
Monteiro, & Reisberg, 1996). Prior to the caregivers completing the behavioral and 
cognitive informant form on behalf of AD patients (N= 20), the qualitative interview (see 
Appendix G) was conducted. I chose six of the participating caregivers to take part in the 
qualitative interview process. I scored the informant questionnaires using the SPSS 
Software, and the qualitative interview (see Appendix G) was organized and evaluated by 
hand. I provided definitions of the stages of AD to each respondent via the background 
demographic questionnaire (see Appendix D) to help them categorize their care 
recipient’s status.  
Demographic Questionnaire 
 The background demographic questionnaire (see Appendix D), which is a 
standard survey questionnaire, was used to gain the necessary background 
information/criteria (Bivin, 2013). It consisted of a 13-item self-report questionnaire. It 
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provided age, gender, age at which AD patient was diagnosed, socioeconomic status, 
education level, and stage of the disease.  
Behavioral Pathology in Alzheimer’s Disease Rating Scale 
 The Behavior Pathology in Alzheimer’s disease Rating Scale (BEHAVE-AD) is 
composed of 25 symptomatic items describing behavioral disturbances (Reisberg, et al., 
1987).  This instrument covers symptoms in seven categories: paranoid and delusional 
ideation, hallucinations, activity disturbances, diurnal rhythm disturbances, 
aggressiveness, affective disorders and anxieties, and phobias (Robert, 2010; Auer, 
Monteiro, & Reisberg, 1996). The BEHAVE-AD scale takes approximately 20 minutes 
to administer (Robert, 2010). The behavior is rated as mild, moderate, or severe. The 
instrument evaluates the importance of each of the 25 symptoms in the seven categories 
using a 4-point severity scale with a score of “0” indicating that the item is not present; a 
score of “1” indicating present of the symptom; a score of “2” indicating the symptom is 
present, generally including an emotional component; and a score of “3” indicating the 
symptom is present, generally with an emotional and physical component. The total 
BEHAVE-AD scores range from 0 to a maximum score of 75. A global scale rating is 
obtained of the degree to which these symptoms are troubling to the caregiver/informant 
and/or dangerous to the patient (Reisberg et al., 2014; Robert et al., 2010; Auer, 
Monteiro, & Reisberg, 1996).   
I received permission to use the BEHAVE-AD Informant Scale via email from 
Barry Reisberg, MD, at NYU Alzheimer’s Disease Center, New York University 
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Langone Medical Center, New York on March 11, 2015 (see Appendix H).  Dr. 
Reisberg’s condition for the scale utility was that it be properly referenced and the 
copyright noted in all reproductions. The BEHAVE-AD Informant was chosen because it 
is an informant-based rating scale and was developed to elicit information obtained from 
caregiver reports (Auer, Monteiro, & Reisberg, 1996). It assesses behavioral symptoms in 
AD patients, independent of comparatively difficult to treat cognitive symptoms (Robert 
et. al, 2010). This instrument had limitations because it was used to evaluate AD patients 
based solely on information from their caregivers (i.e., spouses, children, parents). 
Nonetheless, the instrument had good reliability in discriminating and good validation in 
AD cases, whether non-pharmacological or pharmacological (Reisberg et al., 2014).  
Short Informant Questionnaire on Cognitive Decline in the Elderly 
 The Short Informant Questionnaire on Cognitive Decline in the Elderly 
(IQCODE) is a subjective rating scale that measures cognitive decline from a pre-morbid 
level using informant reports (Jorm, 1994). The instrument was developed by Professor 
Anthony Jorm in 1994 as a brief version of the IQCODE developed by Jorm and Jacomb 
in 1989. I sent Dr. Jorm’s an email to inform him that I would be using this tool (see 
Appendix I). The Short IQCODE is used to assess cognitive decline and dementia in the 
elderly. The informant or caregiver is required to have known the elderly individual for 
ten years or longer in order to provide information that compares his/her present 
performance with 10 years ago. The questionnaire takes about 15 minutes. The score for 
each question is summed and then divided by the number of questions, which are 16 for 
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the Short IQCODE (Jorm, 1994). The range of scores is from 1 to 5 compared with 10 
years ago how is his/her performance. A “1” indicates much improved, “2” a bit 
improved, “3” not much change, “4” a bit worse, and “5” much worse. The Short 
IQCODE (Jorm, 1994) was chosen because it has been proven to be useful for 
individuals who are unable to undergo direct-cognitive testing due to acute illness, lack of 
cooperation or death. Furthermore, this tool is also valuable in screening populations with 
low education and literacy levels. Although the Short IQCODE (Jorm, 1994) was 
developed for self-completion by informants, it has been and can be used as a face-to-
face or telephone interview. Another variation involves the 10-year time frame. A 
number of users have found difficulty in finding informants/caregivers who possess the 
required contact with the subject for over 10 years. As a result, this has led to the 
modification of a 5-year time frame, which was the time frame for this study.  
 The Short IQCODE (Jorm, 1994) has high reliability. It measures a single general 
factor of cognitive decline and validly reflects past cognitive decline, performs at least as 
well as conventional cognitive screening test for dementia. Studies have also compared 
the IQCODE to neuropathological diagnosis (Rockwood et al., 1998; Thomas et al., 
1994). This instrument was significantly correlated with 130 kDa amyloid precursor 
protein in AD patients’ blood (Thomas, 1996). 
Qualitative Interview 
 The qualitative interview (see Appendix G) consisted of two questions. The first 
question allowed caregivers to give their perspectives of what memory/behavioral 
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changes they had observed in their AD care recipients over the past 2 to 5 years. The first 
question had eight subcategories that were semi-structured. The second question allowed 
the caregiver participants to be more general and explain more in detail what they viewed 
as memory/behavioral changes. These qualitative interview questions were chosen to 
explore more detail of what the caregivers observed in their shared experiences with the 
AD population. 
Data Collection and Analysis 
 As mentioned prior, I presented a background demographic questionnaire to 
caregivers from various Alzheimer’s Association caregiver group locations throughout 
Houston and surrounding areas. This particular questionnaire included demographic 
questions about AD care recipients’ age, gender, socioeconomics, meeting DSM-V 
criteria for AD, age at which AD diagnosis was made, stage of the disease, as well as the 
age, length of time caregiver had known care recipient, and the relationship of caregiver 
to AD care recipient (i.e., spouse, adult child, parent, other). Once, this stage of the 
process had been completed, caregiver participants were asked to complete the 
BEHAVE-AD and Short IQCODE Informant Report Forms, as well as provide narratives 
on the cognitive/behavioral changes they had viewed in the AD care recipients through 
use of a structured qualitative interview. Both instruments took approximately 45 minutes 
to administer. 
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Quantitative Analysis  
I used the analysis of variance (ANOVA) for statistical analysis. ANOVA is a 
hypothesis-testing procedure to estimate mean differences between two or more 
populations (Gravetter & Wallnau, 2009). Onset of diagnosis (EOAD or LOAD) was 
analyzed as a between subject variable. Scores on the BEHAVE-AD and Short IQCODE 
were treated as dependent variables. Alpha was set at 0.05. Statistical analysis drawn 
from the sample data (survey answers supplied from the caregiver and symptoms 
endorsed from research instruments) revealed the most salient memory/behavioral 
symptoms, whether patients were of EOAD or LOAD. The prediction after the 
BEHAVE-AD and the Short IQCODE were scored—summing up totals of caregiver 
answers—yield quantitative measures of memory/behavioral symptoms that were 
compared to onset of AD and determined appropriate stage levels, and used with caution 
to generalize to other AD victims. Symptoms on the BEHAVE-AD and the Short 
IQCODE were scored using version 21 of the SPSS program. 
Qualitative Analysis  
Grounded theory has been described as “the most influential paradigm for 
qualitative research in the social science arena today” (Patton, 2002). Grounded theory 
originated out of the collaboration of Glaser and Strauss (1967), who developed a 
methodological approach based on the theory of symbolic interactionism between 1920 
and 1950. This sociological approach posited fluid and dynamic interpersonal processes 
in which meaning was created within and derived from social interactions (Kendall, 
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1999). Grounded theorists cross-examined the meanings created in these social 
relationships by trying to discover how these groups of individuals defined their realities 
based on their understanding of interpersonal interactions (Cutcliffe, 2000), which is why 
I am using this theory.  
I conducted face-to-face/phone interviews in participants’ homes, business/facility 
conference rooms, and public libraries, using grounded theory to gain information that 
gave each caregiver’s perspective. Two open-ended questions were given to 6 of the 20 
participating caregivers by me after I had built and established rapport (see Appendix G). 
I analyzed qualitative data using Braun and Clark’s (2006)  six-phase thematic analysis: 
1) data was gathered/collected from observational data, questionnaire and interview 
statements, and audio recording; 2) data were coded by hand, every two to three lines of 
text was coded with handles identifying key words, concepts, and reflections; 3) codes 
were validated by reading and re-reading the data to integrate codes in order for themes 
to emerge; 4) themes were reviewed, defined, and refined; subthemes were formed; and 
eventually this step allowed patterns to emerge from the data; 5) themes were named and 
descriptions written in order to help communicate meaning to readers; and 6) a data-
driven report was written, making an argument in relation to the research question(s), 
hopefully, convincing the reader of its merit and validity of the analysis. I also included 
these steps in an inductive approach.  
For example, when each caregiver had: (a) provided me their interpretation, 
answers, and understanding of the two interview questions; (b) provided me 
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clarification/elaboration of the two interview questions, tape/audio recordings, notes and 
memos; then (c) I evaluated and compared each caregiver statements and answers my 
final quantitative results. This was done to obtain trustworthiness, which involved 
credibility, transferability, dependability, and confirmability (Lincoln & Guba, 1985).   
Lincoln and Guba (1985) suggested that trustworthiness is the standard by which 
a qualitative study can be judged. The authors explained that the central organizing 
principle, trustworthiness, was linked to standards applied to quantitative studies such as 
validity, reliability, generalizability, and objectivity. There was a series of techniques that 
Lincoln and Guba (1985) mentioned that I used to evaluate qualitative data analysis such 
as establishing credibility, transferability, dependability, and confirmability. 
Furthermore, the additional narrative themes that became salient from qualitative 
interviews, I received from caregivers, can and will shed light on present and future 
treatment plans and/or preventive measures for AD.  
Summary 
 Over the past 150 years, advances in the treatment of heart disease and cancer are 
responsible for postponement of mortality and a marked change in aging bio-
demographics. In addition, improvements in public health and medical care during the 
20
th
 century led to considerable increases in life expectancy (Carrillo et al., 2013). As a 
result, the principal causes of death have shifted dramatically from chiefly infectious 
diseases to cardiovascular disease, cancers, and increasingly, progressive 
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neurodegenerative dementias, in this case, Alzheimer’s disease (Kling, Trojanowski, 
Wolk, Lee, & Arnold, 2013). 
 AD is the fifth leading cause of death among Americans age 65 and older (AA, 
2012). In order to conduct research on human subjects (caregivers), I considered ethical 
issues such as informed consent, privacy, confidentiality, and authorization to disclose 
PHI. I presented these forms to caregivers on behalf of the AD care recipients. In 
addition, to keep participants safe from harm, I addressed this through participant 
protection and rights. 
 The methodological approach I used to examine symptoms and stages of AD 
among participants (EOAD and LOAD patients) was a mixed method design (Creswell, 
2009). I recruited participants from Alzheimer’s Association caregiver groups across the 
Houston Metropolitan and surrounding areas. I used the following instruments to study 
and obtain new information and details about AD: (a) the BEHAVE-AD Informant 
Report form (Appendix E); (b) the Short IQCODE (Appendix F); (c) the qualitative 
interview (Appendix G); and (d) the demographic background questionnaire (Appendix 
D). Once I scored the quantitative instruments through the SPSS program; reached 
saturation for themes and subthemes from qualitative interview questions; and integrated 
both approaches, I obtained detailed results and analyses that are provided in Chapter 4. 
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Chapter 4: Results  
Introduction 
The purpose of this mixed-method study was to determine whether or not 
individuals with EOAD or LOAD experience different behavioral and cognitive 
symptoms, using caregivers as informants. For the qualitative analysis, a qualitative, 
semi-structured interview was used to understand the experiences of caregivers, who 
gave personal perspectives of what they observed while caring for an individual who had 
been diagnosed with EOAD or LOAD. Each interview was audio-taped and then 
transcribed verbatim and coded and categorized in order to create successful, thematic 
outcomes.  
For the quantitative analysis, behavioral symptoms were measured by having 
caregivers fill out the BEHAVE-AD informant questionnaire and the Short IQCODE 
informant questionnaire for memory symptoms. The independent variable was type of 
diagnosis (EOAD vs. LOAD). The dependent variables were behavioral and memory 
symptoms. I conducted a one-way ANOVA analysis to determine if differences existed in 
behavioral and memory symptoms between early- versus late-onset AD individuals. This 
chapter will restate the purpose of the study as well as research questions and hypothesis. 
It will discuss the setting, demographics, data collection process, as well as report data 
analysis and results describing the qualitative components followed by the quantitative 
components. 
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Research Questions and Hypotheses 
 RQ1: Are there differences in cognitive symptoms between EOAD patients and 
LOAD patients? 
 H01: EOAD patients have the same cognitive symptoms as LOAD patients. 
 Ha1: EOAD patients have different cognitive symptoms than LOAD patients. 
 RQ2: Are there differences in behavioral symptoms between EOAD patients and 
LOAD patients? 
 Ho2: EOAD patients have the same behavioral symptoms as LOAD patients. 
 Ha2: EOAD patients have different behavioral symptoms than LOAD patients. 
Demographic Samples and Data Collection 
I used the Alzheimer’s Association’s Houston Southeast Chapter to recruit 
participants from various caregiver support groups. Criteria included that caregivers were 
age 18 and older,  and cared for someone who had been diagnosed with AD before the 
age of 65 (EOAD) or after the age of 65 (LOAD). The diagnosis of AD had to be 
according to criteria in the DSM-V (APA, 2013). Flyers were either posted or hand-
delivered by me to various caregiver support facilities throughout the Houston 
metropolitan area and other surrounding cities and towns (League City, Clear Lake, 
Pasadena, Texas City, Pearland, Missouri City, Sugar Land, Bellaire, Memorial, Lake 
Jackson, and Conroe). Caregivers acted as informants on behalf of the individuals who 
had been diagnosed as EOAD or LOAD.  
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Between October 12, 2015 and March 16, 2016, I presented caregiver participants 
with research packets after they had agreed to participate in the study. Caregiver 
participants contacted me by cell phone or in person after support group meetings. 
Research packets for the qualitative component of the study took 30 to 45 minutes to 
complete, and consisted of informed consent forms, demographic questionnaires and 
qualitative, semi-structured, open-ended interview questions.  
Research packets for the quantitative component of the study took about 45 
minutes to an hour to complete and consisted of informed consent forms, demographic 
questionnaires and two quantitative measures: a) the BEHAVE-AD informant survey, 
used to measure behavioral symptoms, and b) the Short-IQCODE survey, used to 
measure cognitive/memory symptoms. Due to the mixed method nature of this study, I 
used a sequential design (qualitative component followed by the quantitative component). 
Originally, 31 packets were passed out and sent to caregiver support group 
facilities. Twenty (65%) of the 31 packets were returned. Study sample participants  
(N =20) consisted of two groups: EOAD (n=8) and LOAD (n=12). This was a slight 
deviation from the data collection plan I had hoped to pursue, which indicated counts (N= 
26, which were (Group 1, n =13 participants and Group 2, n =13). Each participant in the 
two groups was given a quantitative packet. Consent forms were explained in detail and 
in person to participants. Before they signed and agreed to the study, they were asked if 
they understood the details that were explained to them.  After they indicated 
understanding, consent forms were presented for their signatures. Six of the 20 
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individuals also participated in the qualitative component of the study. They were divided 
into two groups:  Group 1: EOAD (n=3) and Group 2: LOAD (n = 3). Group 1 consisted 
of two men and one woman; Group 2 consisted of two women and one man. 
The qualitative data collection process consisted of a face-to-face qualitative 
interview, which consisted of two, open-ended questions with question one including 
eight (8) short sub-questions. Each participant was audio recorded with a mini tape 
recorder. Each interview was transcribed verbatim.  The quantitative data collection 
process consisted of participants either filling out packets in person, over the telephone, 
or via the internet. Both qualitative and quantitative interviews were conducted in library 
conference rooms, private offices, and in participant homes. Overall demographics for 
this study are presented in Table 1. 
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Table 1 
Subject Demographics of Research Sample (N = 20) 
Variable                 %     N 
 
English Speaking     
   Yes             100.0     20 
 
AD Patient Age 
   59-69                        35.0       7 
   70-79                            30.0       6 
   80-94                            35.0       7 
 
Gender         
   Male               35.0       7 
   Female              65.0     13 
  
Race/Ethnicity      
   Black/African American                         40.0       8 
   Hispanic/Latino              5.0       1 
   White/Caucasian            55.0     11 
 
Marital Status 
   Single                           10.0       2 
   Married             55.0     11 
   Divorced               5.0           1 
   Widowed             30.0       6 
 
Highest Level of Education    
   High school             15.0       3 
   Some college             35.0       7 
   College graduate            30.0       6 
   Post graduate degree            15.0       3 
   No school/college              5.0        1 
 
Economic ($) Status of AD patient 
   1 to 4,999               5.0       1 
   5,000 to 19,999                          15.0       3 
   20,000 to 49,000            35.0                    7 
   50,000 to 69,000            20.0       4 
   100,000 and above            10.0       2 
   Declined to state            15.0       3 
 
Primary Caregiver 
   Yes              85.0     17 
    No              15.0       3 
 
          (continued) 
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Table 1. Subject Demographics (continued) 
Variable                 %     N 
Relationship to care recipient 
   Spouse             35.0       7 
   Adult/Child/Grandchild                         40.0       8 
   Other                                                                     25.0   5 
 
Age at AD diagnosis 
   < 65 years             35.0       7 
   > 65 years             65.0       13 
 
Patient’s Stage of AD 
   Stage 2               5.0       1 
   Stage 3               5.0       1 
   Stage 4             30.0       6 
   Stage 5             15.0       3 
   Stage 6             35.0       7 
   Stage 7             10.0       2    
 
Note: N = 20; < = less than; > = greater than 
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Data Analysis 
Qualitative Component 
 I conducted the qualitative component before the quantitative component. This 
sequence was done purposefully, in order not to taint caregiver informant answers to the 
semi-structured, qualitative interview questions, which asked about behavioral and 
cognitive changes in the care recipients. The questions were similar to those found on the 
BEHAVE-AD and Short-IQCODE questionnaires, which were used in the quantitative 
component of this study. Each caregiver participant told his/her personal perspective of 
what behaviors/cognitive symptoms they observed in their loved ones or patients who 
had EOAD/LOAD.  
The six-phase thematic analysis (Braun & Clark, 2006) was the process used to 
analyze the data. First, the six qualitative interviews were audio-taped and transcribed 
verbatim. Second, each interview was read and coded by hand (identifying key words and 
phrases). Third, interviews were read and re-read; comparisons were made to integrate 
codes and to develop themes. Fourth, themes were labeled as well as subthemes leading 
to various patterns. Fifth, themes were finalized upon reaching saturation. Sixth, themes 
were analyzed to determine alignment with interview questions in order to produce the 
analytical report.  Once the data was coded by hand, the Maxqda program was not 
necessary (as indicated in Chapter 3). However, by not using the Maxqda program, the 
process took much longer. 
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 Participants’ narrative answers to the qualitative interviews questions resulted in 
various codes such as: (a) short-term memory loss; (b) aphasia; (c) patterns of emotions 
(i.e., from happiness to sadness, from jovial to withdrawn to openness, from scared to 
crying to jovial); (d) spending and giving away money; (e) selling personal belongings 
and property; (f) problem eating; (g) problem bathing: (g) problem putting on clothes;   
(h) anxiety; (i) irritation; (j) frustration; (k) depression; (l) paranoia; (m) hallucinations; 
(n) drug abuse; (o) alcohol abuse; (p) fighting; (q) biting; (r) cursing; (s) and screaming. 
The primary themes were: (a) cognitive impairment; (b) mood swings; (c) impulsiveness; 
(d) struggling with activities of daily living; (e) psychological behaviors; and (f) 
maladaptive (adverse) behaviors.  Further analysis is included in the results section of 
qualitative component analysis (Table 2). 
Quantitative Component 
  Table 1 indicated the demographic background of the quantitative component of 
this study. The following research questions were answered after conducting quantitative 
analysis through use of the SPSS software version 21.0 (IBM Corp. Released 2012).  
RQ1: Are there differences in cognitive symptoms between EOAD patients and LOAD 
patients? 
 H01: EOAD patients have the same cognitive symptoms as LOAD patients. 
 Ha1: EOAD patients have different cognitive symptoms than LOAD patients. 
 RQ2: Are there differences in behavioral symptoms between EOAD patients and 
LOAD patients? 
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 Ho2: EOAD patients have the same behavioral symptoms as LOAD patients. 
 Ha2: EOAD patients have different behavioral symptoms than LOAD patients. 
To answer RQ1, I gave caregiver participants the Short-IQCODE, which is a 
subjective rating scale that measures cognitive decline from a pre-morbid level using 
informant reports. Informants were required to have known the individual with 
EOAD/LOAD for at least 5 years. The questionnaire took about 15 minutes to complete 
with a total of 16 questions. The range of scores were from 1 to 5, with “1” indicating 
much improved, “2” a bit improved, “3” not much change, “4” a bit worse, and “5” much 
worse. The independent variable was type of diagnosis (EOAD vs. LOAD) and the 
dependent variables were the outcomes of the 16 questions completed by participants on 
the Short-IQCODE questionnaire. See (Table 3). 
To answer RQ2, I gave each participant (caregiver) the BEHAVE-AD to fill out 
on behalf of the AD patient (EOAD/LOAD). This tool measures 25 symptoms describing 
behavioral disturbances in seven categories (Paranoid and Delusional; Hallucinations; 
Activity Disturbances; Aggressiveness; Diurnal Rhythm Disturbance; Affective 
Disturbances; and Anxieties and Phobias). The instrument evaluates the importance of 
each of the 25 symptoms in the seven  categories using a 4-point severity scale with a 
score of “0” indicating symptom is not present; “1” indicating present of symptom; “2” 
symptom is present with an emotional component; and “3” symptom is present with an 
emotional and physical component. In addition, this instrument allows a global scale 
rating to be obtained which describes the degree to which the behavioral symptoms are 
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troubling to the caregiver and/or dangerous to the patient.  It took 20 to 25 minutes to 
administer the BEHAVE-AD questionnaire.  
Results of Qualitative Component (Qualitative Interview Q1 and Q2) 
 Demographics of caregiver recipients: early-onset AD (EOAD) patients were 3 (2 
men and 1 woman) and late-onset AD (LOAD) patients were 3 (1 man and 2 women). 
The average age of caregiver recipients was 74 years. Half of the AD patients who were 
being cared for by caregivers were Black/African American and the other half were 
White/Caucasian. The primary and sub-themes that emerged out of the data are as 
follows and also listed in Table 2. Caregiver informants were asked to elaborate on Q1: 
Over the past 2 – 5 years, what are some of the things you observed about this person’s 
change in memory/behavior and Q2: What are some of the most favorable/unfavorable 
moments you have observed about this individual’s memory/behavioral changes? 
Following are the primary themes that emerged from the interviews. 
Primary theme 1: cognitive impairment: All of the caregiver informants described both 
early- and late-onset AD patients as having short-term memory loss as well as aphasia. 
One of the three EOAD patients was described as having long-term memory loss. 
Primary theme 2: mood swings: All of the caregiver informants discussed emotional 
patterns that they observed in each of the AD patients. One EOAD patient was described 
as being frightened then began crying and then appeared to be jovial. Three (2 EOAD 
patients and 1 LOAD patient) were described as being in a happy mood, then going from 
sadness to jovial. Two LOAD patients were described as being jovial, then becoming 
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withdrawn, and later appearing very open to teenagers or individuals they were 
socializing/visiting with. 
Primary theme 3: impulsiveness: All of the EOAD patients fell into this theme (category). 
The sub-themes told of how each of the three went though a phase where they did a lot of 
frivolous spending where they began spending money, giving away money, and selling 
off personal belongings. By assessing the present stage of the disease (according to 
Reisberg’s seven stages of Alzheimer’s) the caregiver informants reported the majority of 
the EOAD group to be in stage 4. However, impulsive behaviors were reported to have 
taken place even before the AD patients had been diagnosed. 
Primary theme 4: struggles with activities of daily living: Caregiver informants stated 
that 5 out of the 6 AD patients struggled with or needed help with eating, 
bathing/showering, putting on clothes, brushing his/her teeth, and going to or using the 
bathroom.    
Primary theme 5: psychological behaviors: All of the caregiver informants indicated that 
they observed their care recipients to have periods where they often went through 
anxiousness, agitation, irritability, frustration, depression, paranoia, and sometimes 
hallucinations, depending on the present state of the disease. 
Primary theme 6: maladaptive (adverse) behaviors: One of the EOAD patients was 
reported to have a history of drinking alcohol and using drugs. Many of the other 
individuals in this qualitative study were observed by their caregivers to be aggressive at 
times when they would fight, bite, kick, curse, or scream. These actions were reported to 
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take place prior to the AD patient taking a bath/shower, staff members entering AD 
patient’s room to help them with ADLs; or watching a television program. 
 As indicated in Table 2 the primary themes were: cognitive impairment, mood 
swings, impulsivity, struggles with ADLs, psychological behaviors, and maladaptive 
behaviors. Both EOAD participants #5, #6, #7 (EP5, EP6, EP7) and LOAD participants 
#1, #2, #3 (LP1, LP2, LP3) were reported to have experienced cognitive deficits, 
especially short-term memory.  
Caregiver participants indicated that care recipients’ cognitive symptoms seemed 
to get worse as the disease progressed. Caregiver informants used criteria for caregiver 
recipient stage levels according to Reiberg’s seven stages of AD: LP1, LP2, and EP6 
were  in stage 6 and LP3, EP5, and EP7 were in stage 4 of the disease. In regards to 
aphasia, the majority (2 out of 3) of LOAD caregiver recipients showed common 
characteristics. Wandering seemed to play a role in the majority (2 out of 3) of EOAD 
caregiver recipients. There was an equal number of EOAD and LOAD caregiver 
recipients who experienced mood swings and half (2 out of 4) were in stage 4 and the 
other half (2 out of 4) were in stage 6. The same held true for impulsivity (LP2 and EP6 
were in stage 6; and EP5 and EP7 were in stage 4). The majority (3 out of 5) of caregiver 
recipients who struggled with ADLs were in stage 6 of the disease. As far as 
psychological behaviors, it appeared that both EOAD and LOAD caregiver recipients 
experienced these behaviors at different stages of the disease, which was unlike the 
cognitive deficits that got worse as progression of AD occurred. Maladaptive behaviors 
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were experienced evenly among both EOAD (EP5 – stage 4) and LOAD (LP2 – stage 6) 
care recipients. After comparison of data and emerging themes, the EOAD and the 
LOAD group were both utilized to maximize similarities and differences, as outcomes 
are presented in Table 2. 
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Table 2 
Primary and Sub-themes for Qualitative Analysis (Early- and Late-onset Participant) 
Primary themes         Subthemes            Caregiver/participant extracted response (s) 
 
Cog. Impairment  S-term Memory loss LP1”She has almost virtually no s-term memory” 
                      LP2 “Her s-term memory was basically non-existent”  
                      LP3 “His s-term memory is pretty much non-existent” 
                      EP5 “The next 5 or 10 minutes she don’t remember” 
                      EP6 “No he don’t remember any of the birthdays” 
                         EP7 “He would tell stories that were the same stories” 
                                        __________________________________________________________ 
 Aphasia          LP1 “She can’t remember names or anything.” 
          LP3 “He doesn’t make full sentences” 
          EP7 “He will struggle with words and names” 
 __________________________________________________________ 
 Wandering    LP3 “He drove to the store and ended up walking back 
                        EP5 “She was roaming trying to leave” 
                        EP7 “He got lost in Dallas going to meet his brother” 
______________________________________________________________________________ 
Mood Swings    Emotional Patterns    LP1 “She goes from sadness to euphoria” 
                      LP2 “It’s odd, like on a dime she’s from happy to mean”   
                      EP5 “…5/10 minutes, pass she cries, she’s angry, scared” 
                       EP7 “His mood is better, he is more jovial” 
______________________________________________________________________________ 
Impulsivity       Frivolous Spending    LP2 “Several times/week she paid him $100 for the yard”  
                       EP5 “It’s got to be high dollar, nothing cheap” 
                       EP6 “He was selling off all equipment, spending freely” 
                         Decision-making        EP7 “Gave daughter permission to visit w/o recollection” 
______________________________________________________________________________ 
Struggles with ADLs                        LP1 “They feed her and put her in wheel chair” 
                       LP2 “It’s harder for her to keep up with eating, bathing” 
                       LP3 “He needs help as far as grooming, bathing, eating” 
                       EP6 “He don’t (eating, dressing) I take care of all of that” 
                       EP7 “He has lack of understanding of the shower” 
______________________________________________________________________________                                      
 
               (continued) 
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Table 2. Primary and Sub-themes for Qualitative Analysis (continued) 
 
Primary themes         Subthemes            Caregiver/participant extracted response (s) 
 
Psychological Behaviors                      LP1 “Yea, she gets irritated”  
                        LP2 “Starting to get more agitated and more frustrated 
                        LP3 “He gets frustrated a lot. The look on his face” 
                        EP5 “The voice, the behavior, she is very agitated” 
                        EP6 “They have him on medicine for his depression” 
                        EP7 “He started actively hallucinating the last 3 months” 
______________________________________________________________________________ 
Maladaptive Behaviors Aggression    LP2 “Started getting more combative with staff”           
                     EP5 “She was whipping their behinds up there (staff)” 
______________________________________________________________________________           
 Notes: S-term = short-term; EP5, EP6, EP7 = EOAD participant #; LP1, LP2, LP3 = LOAD participant #; 
ADLs = activities of daily living                     
Results of Quantitative Component (Research Questions 1 & 2) 
 Results of the quantitative-component analysis in this study are summarized in 
Tables 3-11. RQ1 asked if there are differences in cognitive symptoms between EOAD 
patients and LOAD patients. Table 3 describes mean differences for EOAD and LOAD 
patients when it comes to cognitive symptom scores using a one-way ANOVA. In 
regards to EOAD and LOAD patients when it came to separate cognitive symptoms alpha 
was set at .05. There were no statistically significant differences in cognitive symptom 
between EOAD (n = 8) and LOAD (n = 12) groups.  
Table 4 describes Total Cognitive Symptom Scores. Results indicate that there 
were no statistically significant differences in total cognitive symptom scores between 
EOAD and LOAD groups, F (1, 18) = 1.019, p = .326, 2 = 0.05. 
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Table 5 describes the assumption of variances using Levene’s test of equality of 
variances. This test was used to determine whether variances between EOAD and LOAD 
groups for cognitive symptoms are equal. Six of the 16 separate cognitive symptoms 
were statistically significant (which indicates violation of the assumption of 
homogeneity). This included the following: Remembering things that happened recently, 
p = .005; Recalling conversation a few days later, p = .005; Remembering his/her address 
and phone number, p = .005; Knowing how to work familiar machines, p = .028; 
Handling money for shopping, p = .017; and using his/her intelligence to understand, p = 
.028. The assumption of homogeneity of variances was violated, as assessed by Levene’s 
test for variances.  However, looking at the bottom of Table 5, when overall (total) 
cognitive scores were analyzed for EOAD (n= 8) and LOAD (n = 12), the Levene’s test 
is not statistically significant or the group samples were drawn from populations with the 
same variance. Therefore, there was homogeneity of variances, as assessed by Levene’s 
test for equality of variances (p = .184). 
Table 6 provides descriptive statistics for cognitive symptom scores between 
EOAD and LOAD care recipients. Mean score for EOAD was 78.3750 (SD = 2.77) and 
mean score for LOAD was 75.75 (SD = 6.94). Total cognitive scores for EOAD had a 
range from 72-90 and cognitive scores for LOAD had a range from 56-80, indicating 
lower cognitive scores than the counterpart. According to the Short IQCODE 
questionnaire, caregiver participants reported EOAD caregiver recipients as having 
higher cognitive scores than LOAD caregiver recipients. 
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Table 7 provides descriptive statistics for behavioral symptom scores of the 
BEHAVE-AD tool. The mean score for EOAD was 19.25 (SD = 21.37) and the mean 
score for LOAD was 11.08 (SD = 11.86). Total behavioral scores for EOAD care 
recipients ranged from 0-69; whereas, the Total behavioral symptom scores for LOAD 
caregiver recipients ranged from 2-45; again LOAD caregiver recipients indicate lower 
behavioral symptom scores. 
Table 8 summarizes the one-way ANOVA comparing means between EOAD and 
LOAD patients with behavioral disturbances. Simply looking at p-values, there is only 
one indication of behavioral significance between groups (Activity Disturbances), F (1, 
18) = 5.858, p = .026, 2 = 0.25 indicating LOAD caregiver recipients scored higher on 
Activity Disturbances. 
 
Although Table 8 showed at least one mean difference among the group, Table 9 
summarized specific behavioral differences in groups using the Test of homogeneity of 
variances. The Levene’s test was statistically significant and showed that at least two of 
behavioral disturbances violated the assumptions of homogeneity and showed that two of 
the dependent variables (Aggressiveness: p = .044; and Anxieties and Phobias: p = .032) 
between groups were not equal. However, Table 10 indicates that overall results for total 
behavioral symptom scores using the one-way ANOVA reveal that the symptom scores 
or the differences between the symptoms for AD caregiver recipients were not 
statistically significant. Therefore, there was no evidence to reject the null hypothesis. 
There are no differences between EOAD and LOAD behavioral symptoms. This is also 
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indicated in Table 11 where the Levene’s test showed overall behavioral symptom scores 
were not statistically significant indicating that the assumption of homogeneity of 
variances is met. The Levene’s test of equality of variances tests the null hypothesis that 
the population variances are equal. In other words, the group samples are drawn from 
populations with the same variance. Finally, there were no statistically significant 
differences in behavioral symptom scores between EOAD and LOAD groups, F (1, 18), 
1.215, p = .285. 
 
Table 3 
Analysis of Variance (Cognitive Symptoms)      
___________________________________________________________________________________ 
 
        SS  df MS     F Sig. 
___________________________________________________________________________________ 
Remembering things about family Between Groups   .208   1 .208   .677 .421 
    Within Groups 5.542        18 .308 
    Total  5.750  19  
_________ __________________________________________________________________________ 
Remembering recent things  Between Groups   .300   1 .300 2.400 .139 
    Within Groups 2.250 18 .125   
    Total  2.550 19          
____________________________________________________________________________________ 
 
Recalling conversations days later Between Groups   .300   1 .300 2.400 .139 
    Within Groups 2.250 18 .125   
    Total  2.550 19  
____________________________________________________________________________________ 
Remembering his/her address  Between Groups 1.200   1          1.200 4.320 .052 
    Within Groups 5.000 18  278   
    Total  6.200 19    
____________________________________________________________________________________ 
Remembering what day it is  Between Groups   .000   1 .000 .000 1.000 
    Within Groups 3.750 18 .208   
    Total  3.750 19  
____________________________________________________________________________________ 
               (continued) 
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Table 3. Analysis of Variance (continued) 
___________________________________________________________________________________ 
 
        SS  df MS     F Sig. 
___________________________________________________________________________________ 
Remembering where things are kept Between Groups   .075   1 .075 .220 .644 
    Within Groups        6.125 18 .340   
    Total                 6.200 19 
____________________________________________________________________________________  
Remembering where to find things Between Groups   .075   1 .075 .432 .519 
    Within Groups 3.125 18 .174   
    Total  3.200 19 
____________________________________________________________________________________ 
Knowing how to work fam. machines Between Groups   .408   1 .408 1.269 .275 
    Within Groups 5.792 18 .322   
    Total  6.200 19  
____________________________________________________________________________________ 
Learning to use a new gadget/machine Between Groups   .133   1 .133 .655 .429 
    Within Groups        3.667 18 .204   
    Total  3.800 19 
____________________________________________________________________________________ 
Learning new things in general Between Groups   .033   1 .033 .655 .429 
    Within Groups   .917 18 .051   
    Total    .950 19 
____________________________________________________________________________________ 
Following a story in a book or on TV Between Groups   .000   1 .000 .000        1.000 
    Within Groups        5.750 18 .319   
    Total                 5.750 19 
____________________________________________________________________________________  
Making decisions on everyday matters Between Groups   .133   1 .133 .655 .429 
    Within Groups        3.667 18 .204   
    Total                 3.800 19  
____________________________________________________________________________________ 
Handling money for shopping Between Groups   .300   1 .300 1.271 .274 
    Within Groups        4.250 18 .236   
    Total                 4.550 19 
____________________________________________________________________________________ 
Handling financial matters  Between Groups       .133   1 .133 .655 .429 
    Within Groups        3.667 18 .204   
    Total                 3.800 19 
____________________________________________________________________________________  
Handling other arithmetic problems Between Groups       .033   1 .033 .084 .776 
    Within Groups       7.167 18 .398   
    Total                7.200 19  
____________________________________________________________________________________ 
               (continued) 
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Table 3. Analysis of Variance (continued) 
___________________________________________________________________________________ 
 
        SS  df MS     F Sig. 
___________________________________________________________________________________ 
 
Using intelligence to understand reason Between Groups  .408   1 .408       1.269 .275 
    Within Groups       5.792 18 .322   
    Total                6.200 19 
____________________________________________________________________________________  
Note: SS = sum of square; df = degrees of freedom; MS = mean squared; F = F-ratio; Sig. =  p-value  
 
Table 4      
Total Cognitive Symptom Scores 
______________________________________________________________________ 
        SS             df            MS  F Sig._ 
 
Between Groups 33.075          1           33.075  1.019 .326 
Within Groups 584.125       18           32.451   
Total   617.200       19  
______________________________________________________________________ 
Note: SS = sum of squares; df = degrees of freedom; MS = mean squared; F = F-ratio 
Sig. = p-value.  
 
  
Table 5 
Test of Homogeneity of Variances 
_____________________________________________________________________    
                   Levene  Statistic  df1 df2  Sig. 
Remembering things about family,     3.166   1 18 .092 
 friends, e.g., work, birthdays, address 
 
Remembering things that have  21.600   1 18 .000 
 happened recently 
 
Recalling conversations a few days later  21.600   1 18 .000 
Remembering his/her address   32.073   1 18 .000 
 and phone number 
          (continued) 
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Table 5. Test of Homogeneity of Variances (continued) 
_____________________________________________________________________    
                   Levene  Statistic  df1 df2  Sig. 
 
Remembering what day and month it is     .000   1 18       1.000 
Remembering where things are usually kept   1.593   1 18  .223 
Remembering where to find things when   2.000   1 18 .174 
 placed differently 
 
Knowing how to work familiar machines   5.748   1 18 .028 
Learning to use a new gadget or machine   3.168   1 18 .092 
Learning new things in general    3.168   1 18 .092 
Following a story in a book or on TV     .059   1 18 .811 
Making decisions on everyday matters   3.168   1 18 .092 
Handling money for shopping    6.923   1 18 .017 
Handling financial matters e.g. the     3.168   1 18 .092 
 pension, dealing with the bank 
  
Handling other everyday arithmetic                   .333   1 18 .571 
 problems (how much food to buy). 
 
Using his/her intelligence to understand   5.748   1 18 .028 
 and to reason things through 
      Total Cognitive Symptoms    1.911   1 18 .184 
Notes: df1 = Degrees of freedom # 1; Sig. = significance or p-value 
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Table 6 
Descriptive for Total Cognitive Scores 
_______________________________________________________________________  
                       95% CI for M 
              N        M      SD  SE        LL           UL           Min      Max        
 
Early onset  8    78.3750  2.77424        .98084     76.0557   80.6943 72.00 80.00 
Late onset 12   75.7500  6.94295      2.00426       71.3387   80.1613 56.00 80.00 
Total             20   76.8000  5.69949      1.27445     74.1326   79.4674 56.00 80.00 
_______________________________________________________________________ 
Notes: N = Number in population; M = Mean; SD = standard deviation; SE = standard error; CI = 
confidence interval; LL = lower limit; UL = upper limit; Min = minimum; Max = maximum 
 
Table 7         
Statistics for Total Behavioral Symptom Scores  
________________________________________________________________________ 
         95% CI for M 
                          N          M          SD             SE     LL          UL  Min        Max   
 
Early onset   8   19.2500 21.36586    7.55397 1.3877     37.1123       .00  69.00 
Late onset 12   11.0833 11.85870    3.42331 3.5487     18.6180     2.00  45.00 
Total   20   14.3500 16.32330    3.65000 6.7105     21.9895 .00  69.00 
________________________________________________________________________ 
Notes: N = Number in population; M = Mean; SD = standard deviation; SE = standard 
error; CI = confidence interval; LL = lower limit; UL = upper limit; Min = minimum; 
Max = maximum 
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Table 8 
Analysis of Variance (Behavioral Symptoms)  
_______________________________________________________________________      
                                                                 SS      df MS            F      Sig. 
Paranoid and Delusional        Between Groups         32.033 1      32.033      1.226   .283 
              Within Groups       470.167   18      26.120   
               Total        502.200   19 
________________________________________________________________________ 
Hallucinations   Between Groups       2.133      1        2.133       .114   .739   
          Within Groups      336.417    18      18.690   
          Total        338.550    19 
________________________________________________________________________ 
Activity Disturbances        Between Groups     19.200       1     19.200  5.858  .026 
          Within Groups        59.000     18       3.278   
           Total          78.200     19 
________________________________________________________________________ 
Aggressiveness       Between  Groups    10.800        1    10.800  2.113  .163 
         Within Groups        92.000      18      5.111   
               Total                  102.800      19 
________________________________________________________________________ 
Diurnal Rhythm Disturbance Between  Groups    .008     1  .008    .014  .907 
               Within Groups        10.792   18  .600   
               Total          10.800   19 
________________________________________________________________________ 
Affective Disturbances           Between Groups .033     1  .033    .013   .909 
               Within Groups        44.917   18     2.495   
               Total          44.950   19 
_______________________________________________________________________ 
Anxieties and Phobias            Between Groups       8.008   18      .008     .958   .341 
               Within Groups      150.542   18    8.363   
               Total        158.550   19  
________________________________________________________________________ 
Note: SS = sum of squares; df = degrees of freedom; MS = mean squared; F = F-ratio 
Sig. = p-value.   
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Table 9 
Test of Homogeneity of Variances for Behavioral Symptoms 
________________________________________________________________  
  
     Levene Statistic df1 df2   Sig. 
Paranoid and Delusional   1.189  1 18 .290 
Hallucinations                  .628  1 18 .438 
Activity Disturbances               2.775  1 18 .113 
Aggressiveness               4.684  1 18 .044 
Diurnal Rhythm Disturbance              2.449  1 18 .135 
Affective Disturbances     .430  1 18 .520 
Anxieties and Phobias              5.405  1 18 .032 
________________________________________________________________ 
Notes: df1 = Degrees of freedom # 1; Sig. = significance or p-value 
 
Table 10      
Total Behavioral Symptom Scores 
__________________________________________________________  
                     SS              df   MS                F  Sig. 
Between Groups   320.133   1    320.133 1.215 .285 
Within Groups            4742.417 18    263.468   
Total   5062.550 19 
__________________________________________________________ 
 
Note: SS = sum of squares; df = degrees of freedom; MS = mean squared; 
F = F-ratio; Sig. = p-value.  
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Table 11 
Test of Homogeneity of Variances of 
 Total Behavioral Symptom Scores 
__________________________________    
Levene Statistic df1 df2   Sig. 
 
.635    1 18  .436 
__________________________________ 
Notes: df1 = degrees of freedom #1; Sig. = p-value 
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Evidence of Trustworthiness 
The qualitative component of this research study utilized and followed proven 
procedures, the six-phase thematic analysis (Braun & Clarke, 2006) and grounded theory 
(Patton, 2002). This researcher reported a step-by-step approach in the previous 
qualitative component section. This section explained all codes and phrases that emerged 
from re-reading audio-taped, qualitative interviews. Finally, primary and sub-themes 
were presented including examples and extracts as supporting evidence.  Reliability of 
themes was checked against each caregiver participant’s Microsoft Word-typed written, 
audio-taped report for accuracy and confirmation. Validity was obtained by comparing 
codes and themes against the quantitative database used in SPSS that arose out of 
questionnaire responses from caregiver participants. 
The quantitative component of this research study used the BEHAVE-AD 
informant survey that has been successfully used by various researchers. It has good 
reliability in discriminating and good validation in AD cases (Reisberg et al., 2014; 
Robert et al, 2010). The BEHAVE-AD questionnaire is an informant-based rating scale 
that assesses behavioral symptoms in AD patients, independent of comparatively difficult 
to treat cognitive symptoms. It was chosen because it is an informant-based rating scale 
and was developed to elicit information obtained from caregiver reports. In addition to 
the BEHAVE-AD instrument used to measure behavioral symptoms, the Short-IQCODE 
questionnaire was chosen because it has been proven to be useful for individuals who are 
unable to undergo direct-cognitive testing due to acute illness, lack of cooperation, or 
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death. This instrument measures a single general factor of cognitive decline and validly 
reflects past cognitive decline. Researchers have compared the Short-IQCODE to neuro-
pathological diagnosis (Rockwood et al., 1998; Thomas et al., 1994) and it has been 
significantly correlated with amyloid precursor protein in AD patient’s blood (Thomas, 
1996). Both the BEHAVE-AD and Short-IQCODE overall scores (dependent variables) 
reported by caregiver participants were inputted into the SPSS program, using the one-
way ANOVA to analyze groups (EOAD and LOAD). This revealed synthesis of evidence 
that was similar to both qualitative and quantitative outcomes. 
Summary 
 The purpose of this mixed-method study was to determine whether or not 
individuals with EOAD vs. LOAD experience different behavioral and cognitive 
(memory) symptoms. Caregiver participants were used as informants on behalf of AD 
patients. Research questions included RQ1(Are there differences in cognitive symptoms 
between EOAD patients and LOAD patients?) and RQ2 (Are there behavioral between 
EOAD patients and LOAD patients?). 
 Participants/informants were recruited from various caregiver support group 
facilities throughout the Houston metropolitan and surrounding areas. Most of the 
participants were members of the Alzheimer’s Association’s Houston Southeast Chapter. 
The specific criteria requirements included: Must be 18 years of age or older; caring for 
an individual who had been diagnosed with early-onset AD (EOAD)/late-onset AD 
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(LOAD); diagnosis had to be in accordance with criteria in the Diagnostic and Statistical 
Manual of Mental Disorders, Fifth Edition – DSM-V (APA, 2013).  
 Demographic samples and data collection were between October 12, 2015 and 
March 16, 2016. Caregiver participants were divided into two groups (EOAD and 
LOAD) and were given instruments to measure both cognitive and behavioral symptoms. 
Consent forms were provided and discussed and signatures were not obtained until 
understanding of the study was indicated by all participants. Six participants were 
included in the qualitative data collection process of the study. Twenty participants were 
included in the quantitative component of the study. Qualitative caregiver participants 
were given demographic background surveys to fill out; and they were audio-taped in 
person, with the researcher using two open-ended, semi-structured interview questions. 
These interview questions were transcribed in Microsoft word verbatim. The quantitative 
data collection process of the study consisted of participants filling out packets face-to-
face, over the phone, or via the internet. All face-to-face interviews (qualitative and 
quantitative) were conducted in library conference rooms, private offices, and in 
participants’ homes.  
 Results of the qualitative component of the study were presented in Table 2 with 
several primary themes: 1) cognitive impairment; 2) mood swings; 3) impulsiveness; 4) 
struggles with activities of daily living (ADLs); 5) psychological behaviors; and 6) 
maladaptive (adverse) behaviors. According to caregiver participants, 100% of caregiver 
recipients experienced cognitive impairment, specifically short-term memory loss. This 
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was also true for psychological behaviors. It was reported that 6 out of 6 of the caregiver 
recipients went through periods when they experienced anxiousness, agitation, irritability, 
frustration, depression, paranoia, and hallucinations, depending on the present state of the 
disease. 
Results of the quantitative component indicated that (RQ1) there were no 
statistically significant differences in total cognitive symptom scores between EOAD and 
LOAD groups, F (1, 18) = 1.019, p = .326, 2 = 0.05. Results for RQ2 indicated that 
there were no statistically significant differences in behavioral symptom scores between 
EOAD and LOAD groups, F (1, 18) = 1.215, p = .285, 2= 0.06. Findings, limitations, 
and recommendations will be discussed in Chapter 5. 
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Chapter 5: Findings, Limitations, and Recommendations  
Introduction 
The purpose of this study was to explore Alzheimer’s disease, specifically early-
onset AD (EOAD) versus late-onset AD (LOAD) in individuals, and determine whether 
there are differences or similarities among behavioral and cognitive symptoms between 
these two groups. I used a mixed-method approach and caregiver participants were used 
as informants on behalf of EOAD and LOAD patients to answer research questions. In 
this chapter, I provided discussions and findings presented in Chapter 4. In addition, I 
will discuss the limitations of the current study and recommendations for future research. 
Finally, I will offer implications for social change. 
Interpretation of the Findings 
Qualitative Findings   
Two themes that emerged from qualitative data analysis using grounded theory 
and thematic analysis were cognitive impairment and psychological behaviors. When it 
came to cognition, the majority of caregiver participants indicated that care recipients 
suffered from lack of short-term memory. When it came to behavioral observations, the 
majority of caregiver participants indicated that care recipients suffered from 
psychological disturbances that included anxiety, agitation, irritability, frustration, 
depression, paranoia, and hallucinations. This was supported by the narratives they 
provided to the qualitative interview question: Over the past 2 – 5 years, what are some 
of the things you observed about this person’s change in memory/behavior?  
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 Activities of daily living and maladaptive behaviors were two themes that the 
majority of caregiver participants found to be the most challenging to witness or 
experience the care recipient going through. This was supported by the narratives they 
provided to the qualitative interview question: What are some of the most 
favorable/unfavorable moments you have observed about this individual’s 
memory/behavioral changes? 
Quantitative Findings 
 Research Question 1 was used to assess if EOAD patients have different 
cognitive symptoms than LOAD patients.  There was insufficient evidence to reject the 
null hypothesis. EOAD patients have the same cognitive symptoms as LOAD patients. 
Total caregiver recipients (N = 20) were divided into two groups: EOAD caregiver 
recipients (n = 8) and LOAD caregiver recipients (n = 12). Mean score for EOAD was 
78.3750 (SD = 2.77) and mean score for LOAD was 75.75 (SD = 6.94). Total cognitive 
scores for EOAD had a range from 72 – 90 and cognitive scores for LOAD had a range 
from 56 – 80, indicating lower cognitive scores than the counterpart. This was supported 
by questionnaire responses to the Short-IQCODE by caregiver participants.   
Research question 2 was used to determine if EOAD patients have different 
behavioral symptoms than LOAD patients. There was insufficient evidence to reject the 
null hypothesis. EOAD patients have the same behavioral symptoms as LOAD patients. 
Total caregiver recipients (N = 20) were divided into two groups: EOAD caregiver 
recipients (n = 8) and LOAD caregiver recipients (n = 12). Mean score for EOAD was 
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19.25 (SD = 21.37) and mean score for LOAD was 11.08 (SD = 11.86). Total behavioral 
scores for EOAD had a range from 0 – 69 and behavioral scores for LOAD had a range 
from 2 – 45. The maximum EOAD total behavioral score was 69 and the maximum 
LOAD total behavioral score was 45, indicating lower behavioral scores for LOAD 
caregiver recipients. This was supported by questionnaire responses to the BEHAVE-AD 
informant instrument provided by caregiver participants. 
Summary of Findings 
 Research studies indicate that AD is characterized by the onset of impairments in 
memory and executive function, in addition to cognitive and behavioral problems such as 
depression, apathy, and agitation (Wilson, Arnold, Beck, Bienias, & Bennett, 2008). 
Previous studies also indicated that not everyone who develops the disease will have the 
exact same symptoms, or the same rate of progression (AA, 2013).  
In this study, both groups of caregiver participants, whether they cared for an 
individual who had been diagnosed before the age of 65 (EOAD) or after the age of 65 
(LOAD), all agreed that when it came to cognitive symptoms, care recipients showed a 
decline in memory as the disease progressed. However, when it came to behavioral 
symptoms, care recipients exhibited different behavioral symptoms at different stages of 
the disease. In other words, progression of behavioral symptoms did not happen in a 
linear pattern/sequence. Each stage of the disease can have different symptoms or 
sometimes the stages will overlap (AA, 2013). 
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 The demographic background and characteristics of the study included 35% of 
men and 65% of women, with 74.5 years being the mean age of participants. Consistent 
risk factors for AD are age and sex (Kalaria et al., 2008; Perez et al., 2012). Prevalence 
studies such as the Chicago Health and Aging Project (CHAP) and the aging 
Demographics and Memory Study (ADAMS) revealed that about two-thirds of 
Americans with AD are women. Of the 5.2 million Americans older than 65 years with 
AD, 3.4 million are women and 1.8 million are men. 
Limitations 
 Limitations of the study included recruitment of participants, location of 
Alzheimer’s caregiver support groups, and race/ethnic backgrounds. The participants in 
the study were recruited from various support groups that included members from the 
Alzheimer’s Association. Due to time and cost constraints, the quantitative sample size 
(N=20) of the study was small. The locations of the support groups were throughout the 
Houston metropolitan area and surrounding cities and towns. Participants were recruited 
from the Houston Southeast Chapter of the Alzheimer’s Association. As a result, it is not 
possible to generalize the findings of this study to other Alzheimer’s caregiver support 
groups outside of the Houston and surrounding areas or chapters of the Alzheimer’s 
Association outside of Houston or the United States.  
 This study consisted of 40% Black/African American; 5% Hispanic/Latino; and 
55% White/Caucasian participants. Therefore, generalizing this study to other 
races/ethnicities should be carefully considered. 
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Recommendations 
In future studies it would perhaps be more beneficial to interview a larger number 
of caregiver participants, which would bring about a higher number of care recipients in 
regards to races/ethnicities, socioeconomic backgrounds, as well as to include different 
areas in the United States and other countries. Collaboration with previous, present, and 
future researchers could perhaps build on this study. Consistency of successful outcomes 
could result in better protocols and better planning and treatment for AD clients and/or 
patients. Then, perhaps, such a study could be generalized to larger populations in regard 
to culture, race, socio-economic, states, and countries.  
Stage was also a factor in both cognitive and behavioral symptoms. It would be 
beneficial to have care recipients evaluated regularly with the BEHAVE-AD and the 
Short-IQCODE. These instruments could be used by psychiatrists, psychologists and 
other clinicians to assess cognitive and behavioral symptoms at each stage of Alzheimer’s 
disease. Whether or not the client or patient has been diagnosed with EOAD or LOAD, 
the fact still remains that these symptoms are present and are indications that there is a 
need for better treatment planning and prevention.   
Implications for Social Change 
 Continual use of caregiver participants for future studies can ensure that care 
recipients, whether they have been diagnosed at EO AD or LOAD, have a voice. Many 
care recipients in this study were affected by cognitive impairment, i.e., short-term 
memory loss and aphasia, which appeared to get worse as the disease progressed. Quality 
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of life for these individuals could be improved through use of cognitive and behavioral 
measures instituted regularly before and after disease progression.   
 Behavioral and cognitive charts can be created by various facilities and given to 
caregivers to be used from one month to the next.  On a monthly basis, on behalf of their 
care recipients, caregivers could then pass these charts on to treating private-care 
physicians, psychiatrists, psychologists, and/or clinicians. This process would give the 
treating staff an idea of what cognitive decline or behavioral disturbances care recipient 
have experienced over the past month. This protocol or particular instrument could be 
used as standard of care procedures for all patients with AD. This extra information 
would be provided by care recipients/caregivers along with personal backgrounds, bio-
psychosocial history, and medical records when visiting their treating clinicians in private 
practices, hospitals, community emergency centers, nursing homes, or residential 
homes/facilities.  This standard of care procedure could ensure a more accurate 
assessment of the patient, resulting in better diagnosis, treatment, preventative measures 
and successful outcomes. 
Conclusion 
  This mixed-method study was conducted in order to fill a gap in research by using 
sequential use of a qualitative component and materials, followed by a quantitative 
component and materials. Caregiver participants were used as informants and gave their 
responses/perspectives on cognitive and behavioral symptoms that they observed in EOAD 
and LOAD care recipients. Once the data collection phase of the study was complete, I 
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called each participant via phone and went over interviews, questionnaires, and 
demographic surveys to ensure the accuracy of the information. I determined that there 
were no significant variable differences between EOAD and LOAD caregiver recipients.  
  Caregiver participants (N = 6) were interviewed and asked to give personal 
perspectives of what they observed in the EOAD (n = 3) and LOAD (n = 3) care recipients 
they had cared for in the last 2 – 5 years. Two themes that emerged from the qualitative 
portion of the study were: cognitive impairment and psychological behaviors. Caregiver 
participants indicated that care recipients suffered from lack of short-term memory and 
psychological disturbances such as anxiety, agitation, irritability, frustration, depression, 
paranoia, and hallucinations.  
Caregiver participants (N = 20) were asked to fill out survey questions (BEHAVE 
– AD and Short IQCODE). Through the quantitative portion of the study,  I determined 
that there were no significant variable differences (cognitive/behavioral symptoms) 
between EOAD (n = 8) and LOAD (n = 12) caregiver recipients. In other words, results 
revealed that individuals with AD have the same cognitive and behavioral symptoms 
whether they have an early onset or a late onset of the disease (Wilson, Arnold, Beck, 
Bienias, & Bennett, 2008). However, previous studies have indicated that not everyone 
who develops the disease will have the exact symptoms, or the same rate of progression 
(AA, 2013).  
When both qualitative and quantitative results were combined, it was determined 
that there were no differences in cognitive symptoms (cognitive impairment, mood swings, 
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impulsivity, struggles with ADLs), or behavioral symptoms (psychological behaviors, 
maladaptive behaviors), whether experienced by EOAD or LOAD care recipients. The 
cognitive/behavioral symptoms may have been experienced at different stages of the 
disease; however, the same symptoms were present.  
During the collection phase of this study, many of the participants discussed their 
loved one’s cognitive impairments and psychological behaviors. It did not matter whether 
the individual was in their early 50’s and 60’s or in their later 70’s or 80’s. Race, gender, 
socioeconomic status, education, religion, or sexual orientation did not impact these 
impairments or behaviors. Reisberg et al. (2014) suggested that cognition-based symptoms 
of AD occur universally and progressively with the advance of AD and that behavioral 
symptoms of AD are not progressive, but peak at some stage prior to the final stage of the 
disease.  
Age and gender continue to be risk factors for AD (Kalaria et al, 2008; Perez et 
al., 2012). The Chicago Health and Aging project (CHAP) and the Aging Demographics 
and Memory Study (ADAMS) are prevalence studies that revealed that about two-thirds of 
Americans with AD are women. Of the 5.2 million Americans older than 65 years of age 
with AD, 3.4 million are women and 1.8 million are men. Baby-boomers continue to age 
and the majority will be women according to various studies on Alzheimer’s disease (AA, 
2013; Kalaria et al., 2008; Perez et al., 2012). This disease is still one of the top ten causes 
of death in the United States and the fifth leading cause of death among Americans over 
the age of 65 (AA, 2015). This fatal disease is a neurodegenerative brain disorder of 
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unknown cause with neuropathological and neurochemical features. It is usually insidious 
in onset and increases slowly, but steadily. After diagnosis, individuals with the disease 
can live as long as 8 to 20 years (AA, 2013). Unfortunately, there still remains no known 
cure for AD. 
 This study has certain strengths as well as limitations. In order to reduce selection 
bias, participants recruited were from member facilities that belong to the Alzheimer 
Association. In addition, inclusion criterion for diagnosis for AD was used according to 
the DSM-V (APA, 2013). Caregiver roles were that of informants for caregiver recipients 
who had AD—given the fact that some individuals with AD are not always cognitively 
capable, as a result, informants were a positive alternative. Behavioral and cognitive 
instruments (BEHAVE-AD and Short IQCODE) were tools utilized by all participants 
and scored by a statistical software program (SPSS). However, these tools are subjective, 
as well as the perspective of caregivers when it comes to being sensitive enough to 
answer the question or differences in cognitive or behavioral symptoms. Therefore, a 
future study is warranted to possibly assess AD clients more objectively.   
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Appendix A: DSM-V Criteria for Major or Mild Neurocognitive Disorder due to 
Alzheimer’s disease 
A. The criteria are met for major or mild neurocognitive disorder. 
B. There is insidious onset and gradual progression of impairment in one or more 
cognitive domains (for major neurocognitive disorder, at least two domains must be 
impaired). 
C. Criteria are met for either probable or possible Alzheimer’s disease as follows: 
 For major neurocognitive disorder: 
 Probable Alzheimer’s disease is diagnosed if either of the following is present; 
 otherwise, possible Alzheimer’s disease should be diagnosed. 
 1. Evidence of a causative AD genetic mutation from family history or genetic  
 testing. 
 2. All three of the following are present: 
  a. Clear evidence of decline in memory and learning and at least one other  
  cognitive domain (based on detailed history or serial neuropsychological  
  testing). 
  b. Steadily progressive, gradual decline in cognition, without extended  
  plateaus. 
  c. No evidence of mixed etiology (i.e., absence of other neurodegenerative 
  or cerebrovascular disease, or another neurological, mental, or systemic  
  disease or condition likely contributing to cognitive decline). 
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 For mild neurocognitive disorder: 
 Probable Alzheimer’s disease is diagnosed if there is evidence of a causative 
 Alzheimer’s disease genetic mutation from either genetic testing or family 
 history. 
 Possible Alzheimer’s disease is diagnosed if there is no evidence of a causative 
 Alzheimer’s disease genetic mutation from either genetic testing or family 
 history, and all three of the following are present: 
 1. Clear evidence of decline in memory and learning 
 2. Steadily progressive, gradual decline in cognition, without extended plateaus. 
 3. No evidence of mixed etiology (i.e., absence of other neurodegenerative or        
 cerebrovascular disease, or another neurological or systemic disease or  
 condition likely contributing to cognitive decline). 
D. The disturbance is not better explained by cerebrovascular disease, another 
neurodegenerative disease, the effects of a substance, or another mental, neurological, or 
systemic disorder. 
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Appendix B: Stages and Symptoms of AD 
 Stage 1: The No Impairment stage of AD is also known as normal functioning, 
which is associated with having no memory problems. An individual visiting his or her 
medical professional would not show any evidence of dementia (Dowling, Hermann, La 
Rue, & Sager, 2010).  
 Stage 2: The Very Mild Cognitive Decline stage of AD is also known as normal 
age-related changes in an individual. This individual will have memory lapses, i.e., 
forgetting certain words, or where they have put daily objects. But, when interviewed by 
medical professionals, family members or friends, they will not show any dementia 
symptoms (Wilson et al., 2008). 
 Stage 3: Mild Cognitive Decline stage of AD is also referred to as the early-stage 
AD--some can be diagnosed with symptoms, but not all. At this stage of the disease, 
individuals may have problems with memory and concentration. Family members, 
friends, or medical professionals will start to notice the individual having difficulty 
remembering names, performing tasks at work or at home, misplacing valuables, or 
having increased difficulty planning and organizing events or materials (Wilson et al., 
2008). 
 Encoding, storage, and retrieval are three stages of memory operations (Sternberg, 
2009). Therefore, studying memory impairment can give significant insight to cognitive 
dysfunction, which limits autonomy in complex activities performed by those in the early 
dementia stages. Mild cognitive decline, also mild cognitive impairment (MCI) is 
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abnormal cognitive functioning in older adults without the presence of dementia (Rueda 
& Schmitter-Edgecombe, 2009; Van Damme, Belanger, & Belleville, 2009; Ward et al., 
2013; Wilson et al, 2008). MCI is associated with an increased possibility of suffering 
from AD. However, 40 percent of those who suffer from MCI will not necessarily 
develop AD--but examining profiles of MCI cases can often determine which ones will 
develop AD and which ones will not (Pike, Moss, Rowe, & Savage, 2008; Schmitter-
Edgecombe, Greeley, & Woo, 2009). 
 Stage 4: Very Moderate Decline stage of AD is also known as the mild or early-
stage of AD. A medical interview can detect individual symptoms in the areas of 
forgetfulness, impairment in counting numbers or arithmetic, difficulty in paying bills or 
keeping up with finances, and becoming withdrawn or moody in social situations (AA, 
2013).  
 Stage 5: The Moderate Severe Cognitive Decline stage is also known as the 
moderate or mid-stage of AD. At this stage of AD, individuals can still feed themselves 
and go to the bathroom alone. They also remember family members and friends. The 
daily activities that may become difficult include recalling addresses, remembering dates, 
and choosing the proper clothing for the proper seasons or occasions (Gauthier & 
Molinuevo, 2013).  
 Stage 6: Severe Cognitive Decline is also known as the moderately severe or mid-
stage of AD.  Patients/individuals at this stage have significant memory loss with 
considerable personality change. Clients/individuals become unaware of their 
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surroundings, may have problems remembering spouse or caregivers’ names, or need 
assistance with putting on their clothes, e.g., may put pajamas over their daytime clothes 
or put their shoes on the wrong feet. In addition, at this stage of AD, the client can 
become suspicious of his caregiver or spouse motives, due to the client’s personality or 
behavioral changes. It is also common for individuals at this stage of AD to experience 
change in sleep patterns and they are subject to wander if they are not supervised 
properly (AA, 2013). 
 Stage 7: Very Severe Cognitive Decline can also be known as the Severe or late-
stage of AD. Reisberg (2013) explains that patients at this stage of the disease will 
become totally dependent on others to help with daily activities of living. They are unable 
to hold their heads up, to use the bathroom or eat without the assistance of a caregiver. In 
addition, these patients cannot respond to their environment. They are no longer able to 
carry on a normal conversation with others. They may say a few words or phrases. They 
can no longer swallow, their reflexes become abnormal, and they can no longer smile or 
move certain body muscles (Gauthier & Molinuevo, 2013).  
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Appendix C: Cooperation Email  
Email of Cooperation from Alzheimer’s Association (Houston Southeast Chapter) 
Mon, Oct 14, 2013 10:19 am
 
  
 
 Re:          Prospectus on Alzheimer's Disease 
We at the Alzheimer's Association know the value that research can bring to expanding 
our understanding of Alzheimer's disease and the caregiver experience. For that reason, 
we are happy to assist you with accessing care partners through our chapter's programs 
and services. 
What we can offer is this... We serve persons with early stage Alzheimer's disease and 
their care partners through our Early Stage programs. Of particular interest to you may be 
our Learning Together and Discovering Connections groups. These groups serve persons 
with dementia and their care partners by providing education and/or engaging 
programming, followed by separate support groups for PWD and care partners.  
Through those early stage programs you could have access to approximately 15 - 20 care 
partners. In addition, we offer a wide variety of community-based early stage programs 
for which we have a mailing list of about 100 couples. You could have access to 
interested parties from that list, as well. 
In addition, we sponsor about 50 caregiver support groups throughout our 37-county 
region. Those groups meet monthly and we could help you gain access to those 
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caregivers/groups via email/snail mail introduction. Typically about 250 - 350 persons 
participate in support groups each month. 
Here's a link to the various support groups we run, just to give you an idea of their 
locations. http://www.alz.org/documents/tex/support_groupsseptember2013.pdf 
Let me know what you think about the type of access and the types of folks you could 
speak with through our chapter's services. 
Best, 
It was nice speaking with you over the phone yesterday. Attached is my prospectus on 
Alzheimer's disease. I have completed the prospectus and Chapter 2: Literature Review 
of my dissertation. I am now working on the Introduction, which is Chapter 1 of the 
dissertation.  
It is policy that I finish Chapter 3: Methodology section in addition to Chapters 1 and 2 of 
the dissertation in order to get IRB approval from my school. This is why I am contacting 
you at this point because, I would like you to be able to determine what information you 
have available that could benefit my research on the subject of caregivers and what 
information they can provide on the symptoms and stages of the AD patients that they 
care for and observe on a daily or routine basis. Of course, I would not be able to collect 
data until Chapters 1, 2, & 3 of my dissertation has been approved by the IRB. However, 
I am trying to plan ahead by contacting you to give you the attached prospectus in order 
for you to decide if we could be of service to each other. If you agree, I would need to 
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receive a letter of intent from you/your organization indicating such--I have form letters 
that I can send you as well. 
I hope this will be the start of a long relationship, especially working on ways to slow the 
progression or cease the disease, AD, all together. 
Note: I am a doctoral student of clinical psychology at Walden University. I am also 
doing my internship at a private practice in Missouri City/Sugar Land, Texas--my pre-
doctoral year ends on December 9, 2013 and I plan to continue my dissertation course 
through February 2013. I conduct psychotherapy with individuals from age 5 years old to 
78 years old. In addition, I conduct psychological evaluations on adults and child and 
adolescents throughout the week except Thursdays at Ashar Counseling and 
Psychological Services. On Friday mornings from 9:30 AM to 11:30 AM, I attend 
training at Charis Psychological Services in the Gessner/Beechnut Area. 
Regards, 
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Appendix D: Demographic Questionnaire 
1. Do you (caregiver) speak English? ______yes ______ no 
2. What is AD patient age? __________ 
3. What is AD patient gender?  Male___ Female____ Other____ 
4. What is AD patient race/ethnicity? 
a. Asian American 
b. Black/African American 
c. Hispanic/Latino 
d. Native American 
e. White/Caucasian 
f. Other _______________________ 
 
5. AD patient Marital Status: 
a. Single 
b. Married 
c. Separated 
d. Divorced 
e. Widowed 
 
6. AD patient highest level of education: 
a. GED 
b. High school 
c. Some college 
d. College graduate 
e. Post graduate studies 
f. Post graduate degree 
 
7. Economic ($) Status of AD Patient: 
a. 1 to 19,999 
b. 20,000 to 49,999 
c. 50,000 to 69,999 
d. 70,000 to 99,999 
e. 100,000 and above 
 
8. Are you the primary caregiver (provide day to day care)? Yes_______ No________ 
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9. What is your relationship to the care recipient? 
a. Spouse 
b. Adult Child/Grandchild 
c. Other _______________________ 
 
10. How long have you been a caregiver to AD patient? Year(s)____ Month(s)____. 
11. Approximate hours/day provided to AD patient? _____ 
12. What age was patient when he/she was diagnosed with AD: Less than 65 years 
old?____ or  More than 65 years old?____ 
13. Patient’s stage of AD (AA, 2013). Choose from the following by circling the correct 
letter: 
a. Stage 1 (No Impairment/Normal functioning). 
b. Stage 2 (Very Mild Cognitive Decline -- Normal age related changes--forgetting 
certain words, forget where they put things, no dementia problems). 
c. Stage 3 (Early stage of AD/Mild Cognitive Decline -- memory problems, loss of 
concentration, difficulty remembering names, cannot perform tasks at home or at work, 
problems planning and organizing events or materials). 
d. Stage 4 (Very Moderate Decline/Mild or Early Stage -- forgetfulness, impairment in 
counting or arithmetic, difficulty in paying bills or keeping up with finances, becomes 
moody or withdrawn in social situations). 
e. Stage 5 (Moderate Severe Cognitive Decline/Moderate or Mid-Stage of Ad -- can feed 
themselves, go to the bathroom alone, remember family and friends, problems with 
recalling addresses, dates, choosing right clothing for the proper seasons or occasions). 
f. Stage 6 (Severe Cognitive Decline/Moderately Severe or Mid-Stage of AD -- 
significant memory loss, personality/behavioral change, is unaware of environment, 
problems remembering caregiver or spouse’s name, need assistance putting on clothes--
may put shoes on wrong feet or may put pajamas on over their clothes, becomes 
paranoid/suspicious of caregiver motives, change in sleep pattern, patient may wander off 
if not supervised properly). 
g. Stage 7 (Very Severe Cognitive Decline/Severe or Late-Stage of AD -- patient is 
totally dependent on caregiver to help with activities of daily living, need assistance with 
holding their heads up, eating, and using the bathroom; cannot respond to their 
environment, can only say a few words, can no longer hold a conversation with others, 
can no longer swallow, they do not have the use of their muscles, reflexes are abnormal, 
and possibly death occurs). 
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Appendix E: Behavioral Pathology in Alzheimer’s Disease 
(BEHAVE-AD) 
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Copyright © 1986 by Barry Risberg, M.D. (all rights reserved). 
The BEHAVE-AD has been “reproduced with permission.” 
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Appendix F: Short IQCODE 
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Appendix G: Qualitative Interview  
1. Over the past 2 – 5 years, what are some of the things you observed about this 
person’s change in memory/behavior? 
a. Can you elaborate on his/her memory when it comes to their spouse, 
significant other, family, friends?  How does he/she react to them? 
b. Can you elaborate on his/her memory when it comes to family and 
friends’ addresses, birthdays, occupations, etc.?  What are her actions? 
c. What are some of the things that he/she does that make you know that she 
remembers or forgets the time, date, and place? How does he/she behave if 
they can or can’t remember? 
d. What about when it comes to remembering how to work a particular 
machine/gadget around the house? How does he/she react if they can or 
can’t remember? 
e. How does he/she react to handling money or financial situations? 
f. What about making normal day-to-day decisions (what to eat, what to 
wear, when to use bathroom, when to brush teeth)? What are some of the 
ways she reacts to these activities? 
g. Learning new things in general? How does he/she react? 
h. Remembering events that happened the day before? If they can remember, 
how do they react/if they can’t remember, how do they react? 
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2. What are some of the most favorable moments you have observed about this 
individuals memory/behavioral changes? What are some of the most unfavorable? 
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Appendix H: Permission to use BEHAVE-AD Instrument 
I would be pleased to provide you with permission to use the BEHAVE-AD in your 
research in the Clinical Psychology Program at Walden University in association with 
your dissertation and with the publication of the dissertation provided that you agree to 
the following conditions: 
  My conditions are that the scale is properly referenced and that the copyright is noted in 
all reproductions. 
 The complete reference for the BEHAVE-AD is: 
             Reisberg, B., Borenstein, J., Salob, S.P., Ferris, S.H., Franssen, E., Georgotas, A. 
Behavioral symptoms in Alzheimer's disease: Phenomenology and treatment.Journal of 
Clinical Psychiatry, 1987, 48 (5, suppl.): 9-15. 
 The copyright notice for the BEHAVE-AD is as follows: 
          Copyright ©1986 by Barry Reisberg, M.D., all rights reserved. 
You should also note that the scale has been "reproduced with permission." 
 This permission will extend for a period of 8 years after you reply agreeing to the above 
conditions.  
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Sent: Tuesday, March 10, 2015 7:11 PM 
Subject: Permission Request 
Thank you for returning my call on Tuesday, March 10, 2015 in regards to my request to 
have written permission to include your BEHAVE-AD tool in my dissertation. 
I am a doctoral student in the clinical psychology program at Walden University. My 
dissertation is on Alzheimer's disease and I am comparing early-onset AD patient 
symptoms to late-onset AD patient symptoms using caregivers as informants. Your 
Behavioral pathology in Alzheimer's Disease (BEHAVE-AD) tool will be used to 
measure behavioral symptoms and I will be using the Short Form of the Informant 
Questionnaire on Cognitive Decline in the Elderly (Short IQCODE) to measure cognitive 
symptoms. My research question is: Are there differences in symptomology between 
EOAD patients and LOAD patients?  
In addition to using the BEHAVE-AD as a measuring tool, once my research is complete, 
Walden University will be publishing it as an appendix at the end of my dissertation. 
I hope to hear from you soon. 
Thanking you in advance, 
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Appendix I: Email to/Acknowledgment (Use of Short IQCODE) 
Subject: RE: Short IQCODE use in dissertation study 
Date: Tue, Aug 18, 2015 8:00 pm 
 
Thanks for letting me know about your project. Best wishes for it. 
Regards 
______________________________________________________________________________ 
Sent: Wednesday, 19 August 2015 10:51 AM 
Subject: Short IQCODE use in dissertation study 
  I am a graduate student at Walden University in the Doctoral Clinical Psychology Program 
(United States). My dissertation topic is "Comparative memory/behavioral symptoms of 
Alzheimer's disease: EOAD vs LOAD." 
 This email is to inform you of my plan to use your instrument the Short Form of the Informant 
Questionnaire on Cognitive Decline in the Elderly (Short IQCODE) as a tool to obtain information 
from potential participants (caregivers to Alzheimer patients/victims) for my dissertation research. 
 I would like to thank you for creating the Short IQCODE, it is an asset greatly appreciated that 
will enable me to conduct my research study. If you have any questions or concerns, please do 
not hesitate to contact me at the email or telephone number below. 
  
Regards, 
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Appendix J: Protecting Human Research Participants 
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Appendix K: Flyer 
 
 
Opportunity to be a participant in a dissertation 
study if  
YOU are over 18 and a CAREGIVER to 
SOMEONE who is one of the following: 
  Diagnosed with Alzheimer’s disease before 
65 years old (Early onset AD) or 
  Diagnosed with Alzheimer’s disease after 65 
years old or later (Late onset AD) 
♦♦♦♦♦♦♦♦♦
 
